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ABSTRACT 
The signals and the molecular mechanisms that regulate the replication of 
terminally differentiated β cells are unclear.  In this thesis I report the 
identification of a gene encoding transmembrane protein 27 (TMEM27) in 
pancreatic β cells.  Expression of Tmem27 is reduced in Tcf1–/– mice, which 
exhibit defects in proliferation, and is increased in islets of ob/ob, db/db and aP2-
Srebp-1c transgenic mice with marked hypertrophy of the endocrine pancreas. 
Tmem27 is expressed in hormone positive cells at early stages of pancreas 
development and becomes restricted to pancreatic β cells in the mature pancreas. 
Biochemical characterization revealed that the Tmem27 exists as a dimer and that 
its extracellular domain is glycosylated, cleaved and shed from the plasma 
membrane. The cleavage process of Tmem27 is β cell-specific and does not occur 
in other cell types. Overexpression of full-length Tmem27, but not the truncated 
or soluble protein, in MIN6 cells leads to increased thymidine incorporation, 
whereas silencing of Tmem27 using RNAi results in a reduction of cell 
replication. Furthermore, transgenic mice with increased expression of Tmem27 
in pancreatic β cells exhibit increased β cell mass compared to their control 
littermates. The following results identify a novel pancreatic β cell-shed protein 
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1.1 Introduction to diabetes mellitus 
The number of people with diabetes has been rising at a disconcerting rate 
worldwide with significant increases in the last two decades.  As of 2001, an 
estimated 150 million people globally had diabetes and this number is expected 
to reach 220 million people by 2010 and 300 million by 2025 (Zimmet et al., 2001).  
Diabetes is a heterogeneous group of disorders characterized by high fasting 
blood glucose levels (ADA Report, 2001).  There are two major forms of diabetes. 
Type 1 diabetes, also known as juvenile-onset diabetes, occurs as a result of an 
autoimmune mediated destruction of the insulin producing β cells of the 
pancreas.  The more prevalent type 2 diabetes accounts for more than 90% of 
people with diabetes and is a complex disease that develops as a result of both 
genetic and environmental factors.  Diabetics of both types develop serious 
micro- and macrovascular complications that affect the kidney, heart, 
extremities, eyes,and lead to renal failure, heart attack, gangrene, stroke, and 
blindness.  Thus diabetes already imposes a considerable burden on health-care 
systems and will develop into a major international public health threat in the 
future. 
Type 2 diabetes may develop as a result of various defects in diverse 
molecular pathways.  The precise regulation of plasma glucose levels requires a 
balance between the function of pancreatic β cells and the responsiveness of 
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metabolic tissues such as muscle, liver, and fat.  Genetic disposition as well as 
obesity and sedentary lifestyle are contributing factors to type 2 diabetes, which 
involves insulin resistance and/or dysfunctional β cells.  Hence, defects in β cell 
growth and function play a central role in the pathophysiology of both type 1 
and 2 diabetes.  
The pancreas is derived from the endoderm and consists of three distinct 
cell populations called the endocrine, acinar, and ductal cells.  The acinar cells 
make up the exocrine pancreas that secrete digestive enzymes into the intestine. 
The endocrine cells are the major constituents of islets that secrete hormones into 
the blood stream (Slack, 1995).  Pancreatic islets are comprised mainly of β cells 
(80%) that secrete insulin and to a lesser extent of α cells (10-15%) that secrete 
glucagon, δ cells that secrete somatostatin, PP cells that secrete pancreatic 
polypeptide and ε cells that express ghrelin (Prado et al, 2004).   
 
1.2 Regulation of islet mass 
Endocrine hormones tightly regulate energy metabolism in the body and 
islet mass is dynamic and adaptable in response to metabolic demand.  In a 
number of metabolic states such as growth, pregnancy, insulin resistance due to 
obesity and in various injury models, islet mass seems capable of compensating 
both functionally and morphologically.  In fact, only 15-20% of people with 
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obesity or severe insulin resistance become diabetic and most people are able to 
maintain normoglycemia due to β cell compensation (Bonner-Weir, 2000).  This 
phenomenon is shown in humans (Kloppel, 1985) and in experimental rodent 
models.  In Zucker fa/fa rat, a nondiabetic animal model of obesity, β cell mass 
increases 4-fold compared with lean controls (Pick, 1998). During pregnancy, β 
cell mass adjusts considerably and it has been shown in the rat that β cell mass 
increases by about 50% due to increased β cell proliferation induced by placental 
lactogen and increased cell volume as a functional adaptation.  Β cell mass also 
continues to increase during postnatal growth and in rodents it is linearly 
correlated with body weight (Bonner-Weir, 2000). β cells are also capable of 
decreasing their mass when it is necessary.  After pregnancy, a rapid decrease of 
the β cell mass occurs in postpartum rats (Marynissen et al., 1983).  This is 
accompanied by decreased β cell replication and β cell size, and by an increased 
frequency of apoptosis (Scaglia et al., 1995). 
The mass of β cells is governed by the balance of β cell growth 
(replication) and β cell death (apoptosis) (Bonner-Weir, 2000; Lingohr et al., 2002; 
Butler et al., 2003; Flier et al., 2001).  However, the identity of the factors that 
control β cell mass remains elusive.  In the adult organism, maintenance of β cell 
mass involves replication of preexisting cells (Dor et al., 2004) and recent 
evidence substantiates that regeneration of islets even after injury does not 
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display recapitulation of neogenesis present during development (Lee et al., 
2006).  Thus, understanding how β cell mass is regulated is important to design 
rational approaches to prevent pancreatic β cell loss and to expand β cells for 
transplantation in type 1 diabetes. 
During development, β cells are generated from a population of 
pancreatic progenitor cells (Edlund, 2002; Wilson et al., 2003).  The β cells that 
differentiate from progenitor cells are postmitotic, and direct lineage tracing 
studies indicate that a population of progenitor cells persists throughout 
embryogenesis to allow the differentiation of new β cells (Dor et al., 2004; Gu et 
al., 2002; Gradwohl et al., 2000).  In the neonatal period new β cells are formed by 
replication of differentiated β cells, which results in a massive increase in β cell 
mass (Finegood et al., 1995; Svenstrup et al., 2002).  In adulthood there is little 
increase in the β cell number except in conditions of increased demand and the 
growth stimulatory signals in pathological insulin resistant states are not well 
understood. 
Several mouse models of insulin resistance and diabetes, such as the ob/ob 
and db/db mice or mutant mice created by inactivation of the gene for insulin 
receptor substrate-1 (Irs-1) or double heterozygous knockout of the insulin 
receptor and Irs-1, exhibit marked islet hyperplasia (Bock et al., 2003; Tomita et 
al., 1992; Gapp et al., 1983; Kulkarni et al., 2004 and Kahn, 2003). In contrast, loss 
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of Irs-2 function leads to a dramatic reduction of β cells and diabetes (Withers et 
al., 1998). Glucose itself is known to stimulate β cell replication (Topp et al., 
2004), however, many of the above mouse models increase their total islet mass 
before the onset of detectable hyperglycemia. Furthermore, in most cases the 
hyperplastic response bears no relationship to the level of hyperglycemia, 
suggesting that factors independent of glucose are likely to contribute to the islet 
growth.    
 
1.3 Overview of pancreas development 
Pancreas development in the mouse begins at embryonic day 9 (E9) with 
the emergence of dorsal and ventral epithelium buds between the stomach and 
duodenum (Figure 1).  The molecular machinery that drives gut epithelium 
towards a pancreatic fate is not completely understood, however, a temporally 
and spatially regulated framework of transcription factors involved in the 
development of pancreatic tissue has been described.  Pdx1 is one of the earliest 
expressed transcription factors in the pancreatic epithelium.  It has been showed 
that initiation of either bud can take place without Pdx1 expression. Yet, Pdx1 
expression is crucial for growth and morphogenesis of the bud epithelia 
(Ahlgren et al., 1996; Offield et al., 1996).   
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The nascent buds go through remarkable growth and branching before 
fusing at E12.5 (Figure 2).  In this early stage of pancreatic primordium 
expansion, there are clusters of cells that express both glucagon and insulin.  The 
exact role of these cells is not obvious as they have been shown not to be the 
progenitors of hormone positive cells that make up the islet in the adult animal 
(Herrera, 2000), although an ex-vivo study using pancreatic tissue from E11 
mouse embryos showed that antagonizing glucagon at this stage leads to 
inhibition of β cell differentiation (Prasadan et al., 2002).  Between E13.5 and 
E15.5, there is a wave of endocrine and exocrine cell differentiation and number 
of insulin and glucagon positive cells as well as acinar cells expressing digestive 
enzymes increases dramatically.  Towards the end of the fetal gestation at E18.5, 
development of pancreas morphology is complete as endocrine cells are 
organized into islet structures located among the acinar cells.  Neogenesis of β 
cells continues through the initial days of neonatal period when the pancreatic                        
Figure 1.  Location of the dorsal
and ventral pancreatic buds in
the developing embryo.
Adapted from Slack, 1995. 
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islets become glucose responsive.  Neogenesis can be defined as the formation of 
new β cells by the differentiation of previously insulin negative precursor cells 
and this process usually stops shortly after birth.  Thereafter, β cell mass is 
regulated through an interplay between replication and apoptosis.  
 
1.4 Network of transcription factors regulate β cell development and function 
  Several genetic interactions play a role in the early development of gut 
endoderm. Induction followed by patterning of pancreas involves tissue and cell-
specific expression of transcription factors and is regulated by morphogens 
produced by mesodermal mesenchyme and vascular endothelium in a temporal 
and spatial fashion (Lammert et al., 2003).  Development programs of the dorsal 
and ventral buds of the pancreas are not identical as they are two independent 
endodermal domains receiving distinct signals from their surrounding tissues.  
Figure 2.  Branching morphogenesis in the 
embryonic pancreas.  Yellow shading marks the 
cells that express Pdx-1 and the gray shading shows 
the differentiated early endocrine cell clusters.  The 
diagram depicts the dorsal bud specification. 
Diagram is adapted from Kim and MacDonald, 
2002. 
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Dorsal bud grows in close proximity to notochord and its development requires 
signals from the notochord to repress the signaling factor sonic hedgehog in the 
presence of Pdx-1 expression (Apelqvist et al., 1997).  Ventral bud develops in 
close connection to the liver and bile duct epithelium.  Signals that drive ventral 
pancreatic bud differentiation are not completely understood, however, 
pancreatic lineage appears to be more of a default pathway as cardiac mesoderm 
signaling defines liver cells and lack of this signaling leads to pancreas   
specification.  Recent evidence implicates the homeobox protein, Hex, in control 
of positioning endoderm cells and specifying the ventral bud (Bort et al., 2004).  
Several transcription factors are critical regulators of the endodermal 
development and their expression in certain stages along with defined 
interacting partners determine differentiation programs of individual cell types 
(Habener et al., 2005).  Trancription factors Tcf-1, Tcf-2, Foxa2, HNF4α and Hnf6 
(Onecut 1) are all expressed in the pancreatic progenitor cells that are defined by 
activation of Pdx-1 and Hb9.  As shown in Figure 3, determination of different 
cell lineages in the pancreas involves activation of a cascade of transcription 
factors.  Exocrine cell precursors express Ptf1a (p48) and endocrine cell fate is 
established by transient expression of the basic helix-loop-helix (bHLH) 





Phenotypic results of gene-specific knockout animals defined the 
expression requirements of various transcription factors (Table 1) in the 
development of different pancreatic cell types.  NeuroD/Beta2 is expressed in 
precursors of both α and β cells and a terminally differentiated β cell 
furthermore requires activation of Pax4, MafA, Nkx2.2, and Nkx6.1.  
Organogenesis of the pancreas is defined by restricted expression of the above 
transcription factors and most of the same factors also play a role in maintaining 
the terminally differentiated cells.  For example, Pdx-1 is widely expressed in 
early development of pancreas; however, in late fetal gestation its expression is 
gradually restricted to β cells and δ cells.  The importance of transcription factors 
Figure 3.  A cascade of transcription 
factor activation determines 
specification of cell lineages in the 
developing pancreas. 
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in endocrine cell development and function has also been emphasized in humans 
as mutations in transcription factors TCF1, TCF2, HNF4α, IPF-1 (Pdx-1), 
NEUROD/BETA2 result in a monogenic form of diabetes called the maturity-
onset diabetes of the young (MODY).  In the β cell, Tcf1 (MODY3), Pdx-1 
(MODY4), and NeuroD (MODY6) are all shown to be direct regulators of insulin 
gene expression.  Moreover, these transcription factors along with HNF4α 
(MODY1), Tcf2 (MODY5), Hnf6 and Foxa2 exist in a transcriptional network 
where they regulate each other’s expression.  Thus the determination of the 
identity and the function of the β cell are achieved through expression of a 
unique combination of transcription factors in a specific gene regulatory 


















Pancreas phenotype in 
null mutant mice 
 
References 
Foxa2 E5.5-6.5 All cells Embryonic lethal due to 
lack of foregut formation 
Ang et al., 
1994 
Hlxb9 E8  Dorsal bud fails to develop; 
reduction of β cells in 
remnant pancreas. 
Li et al., 1999 
Pdx-1 E8.5 β cells Pancreas agenesis Jonsson et 
al., 1994 
Isl-1 E9 β, α, δ, PP cells 
Dorsal 
mesenchyme 
Endocrine cells are absent. Ahlgren et 
al., 1997 
Hnf6 E9.5  Impaired endocrine cell 
differentiation; Ngn3 
expression is reduced. 
Jacquemin et 
al., 2000 
Ngn3 E9-9.5  Endocrine cells and their 
precursors are absent. 
Gradwohl et 
al., 2000 
Beta2/NeuroD E9.5 β, α, δ, PP cells Islet malformation and 
reduced endocrine cells. 
Naya et al., 
1997 
Pax6 E9-9.5 β, α, δ, PP cells Islet malformation. α cells 
are absent. 
Sander et al., 
1997 
Pax4 E9.5 β, δ, PP cells β and δ cells are absent. 
Growth retarded mouse 
dies 3-5d after birth. 
Sosa-Pineda 
et al., 1997 
Nkx2.2 E9.5 β, α, PP cells Reduced islet mass and 
absence of β cells.  Mouse 
dies due to hyperglycemia. 
Sussel et al., 
1998 




1.5 Maturity-onset diabetes of the young (MODY) 
MODY is a clinically heterogeneous disorder and accounts for approximately 5-
10% of patients with type 2 diabetes.  MODY is characterized by autosomal 
dominant inheritance, an early onset usually before 25 years of age, and 
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development of marked hyperglycemia with a progressive impairment in insulin 
secretion (Shih and Stoffel, 2002).  Studies using genetic linkage and candidate 
gene approaches have led to mutations in six genes that cause MODY in people.  
The MODY2 gene encodes the glycolytic enzyme glucokinase (GCK) important 
for glucose sensing in β cells (Frougel et al., 1993).  Glucokinase catalyzes the first 
rate-limiting step in glycolysis and is crucial for generating the metabolic signal 
for insulin secretion (Matschinsky, 1990).  Heterozygous mutations in the GCK 
gene lead to a partial deficiency of this enzyme and are associated with MODY2; 
homozygous mutations result in a complete deficiency of this enzyme and lead 
to permanent neonatal diabetes mellitus (Njolstad et al., 2001).  Glucokinase-
deficient mice exhibit a similar phenotype to MODY2 patients as mice that lack 
GCK activity die perinatally with severe hyperglycemia resembling rare forms of 
neonatal diabetes and heterozygous mice have elevated blood glucose levels and 
reduced insulin secretion.  The importance of GCK activity in β cells is reinforced 
with further experiments in the GCK-deficient mice, which show that recovering 
expression of glucokinase only in β cells can rescue homozygous null mice from 
perinatal death (Grupe et al., 1995).  Several heterozygous activating GCK 
mutations that cause hypoglycemia have also been reported in humans (Glaser et 
al., 1998; Christesen et al., 2002; Gloyn et al., 2003). 
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 MODY4 is a rare form MODY caused by an inactivating mutation in the 
IPF-1/PDX-1 gene.  This single nucleotide deletion (Pro63fsdelC) has been 
described in a patient with pancreatic agenesis (Stoffers et al., 1998).  This patient 
inherited the mutant allele from his parents who were heterozygous for the same 
mutation (Stoffers et al., 1997).  Heterozygous family members have early-onset 
diabetes (Stoffers et al., 1997b).  Other PDX-1 mutations have been described to 
predispose carriers to diabetes and functional analysis of these variants 
suggested that these mutations might lead to a progressive impairment of β cell 
function and glucose homeostasis collectively with other risk factors (Hani et al., 
1999; Macfarlane et al., 1999).  Mice with targeted disruption of the Pdx-1 gene 
also fail to develop a pancreas and moreover, β cell-specific inactivation of Pdx-1 
gene leads to a loss of β cell phenotype and diabetes (Jonsson et al., 1994; 
Ahlgren et al., 1998).  In both humans and rodents, PDX-1 appears to be a key 
regulator in early pancreas formation and in maintenance of insulin expression 
and normoglycemia. 
 MODY6 is caused by mutations in the bHLH transcription factor 
NEUROD1/BETA2.  NEUROD1 mutations so far have been described in two 
families with autosomal-dominant inheritance. One family showed a clinical 
phenotype that resembles type 2 diabetes with high fasting serum insulin levels. 
The second family met the criteria for MODY as three carriers in the family 
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displayed onset of diabetes before 25 years of age and five family members 
required insulin treatment consistent with β cell dysfunction and low 
endogenous insulin secretion (Malecki, et al., 1999).  NEUROD1 regulates insulin 
gene expression by binding to its promoter and plays an important role in 
endocrine cell type determination in development.  Mice deficient in NeuroD1 
function have abnormal islet morphology, overt diabetes, and die after birth 
(Naya et al., 1997).    
 Transcription factors HNF4α and Tcf1 regulate each other’s expression 
and consequently clinical features of MODY1 and MODY3 are similar. Both 
MODY1 and MODY3 patients show progressive deterioration of glycemic 
control associated with a decrease in insulin secretion (Fajans et al., 1993).  
HNF4α is a member of the nuclear receptor family of transcription factors and 
plays a critical role in development, cell differentiation, and metabolism of 
pancreatic islets as well as visceral endoderm, liver, intestine, and kidney (Stoffel 
and Duncan, 1997).  Molecular studies indicate that HNF4α deficiency results in 
impairment of insulin secretion by dysregulation of pancreatic islet gene 
expression and the extent of regulation by HNF4α  has recently been further 
substantiated using a combined chromatin immunoprecipitation with a custom 
promoter microarray (Odom et al., 2004).  The authors discovered that over 40% 
of the active promoters in pancreatic islets were bound by HNF4α including 
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those of genes involved in glucose metabolism and insulin secretion.  In the same 
study, cross-regulation of TCF1 and HNF4α has also been confirmed as they 
were found to occupy each other’s promoters.  The HNF4α-deficient mouse is 
embryonic lethal, however, new data on mice generated by β cell-specific 
deletion of HNF4α show that the mice exhibit impairment of glucose-stimulated 
insulin secretion, consistent with MODY1 phenotype, and a possible mechanism 
for this defect may include altered activity of K-ATP channel (Miura et al., 2006).   
MODY5 transcription factor TCF2 is structurally related to TCF1.  TCF1 
and TCF2 are expressed in a variety of tissues and can form homodimers as well 
as heterodimers with each other.  MODY5 patients are also characterized by 
reduced insulin secretion; however, their diabetic phenotype is often 
accompanied by progressive nondiabetic renal dysfunction (Nishigori et al., 
1998).  Selective deletion of the Tcf2 gene in β cells of mice manifests in impaired 
glucose tolerance and impaired glucose-dependent insulin release (Wang et al., 
2004). 
The most common form of MODY is MODY3 caused by mutations in the 
TCF1 gene.  Depending on the racial group, MODY3 accounts for 15-73% of all 
described MODY patients (Frayling et al., 2001).  TCF1 is a homeodomain 
transcription factor composed of an N-terminal dimerization domain, a POU-
homeobox DNA-binding domain, and a C-terminal transactivation domain.  
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MODY3 phenotype in humans manifests defective glucose utilization, insulin 
secretion, and glucose disposal (Surmely et al., 1998).  In fact, it has been 
reported that insulin sensitivity is actually increased in MODY3 patients making 
the role of β cell pathogenesis particularly central in MODY3 (Frayling et al., 
2001). The most common mutation of the TCF1 gene is an insertion of C in the 
poly C tract around codon 291 (P291fsinsC) most likely due to slipped 
mispairing during DNA replication.  Mutations in the TCF1 gene mainly cause 
diabetes through haploinsufficiency. However, it has been shown that 
P291fsinsC has a dominant negative effect when it is overexpressed in cell lines 
(Yamagata et al., 1998).  Two experimental animal models of MODY3 have been 
generated to investigate the role of Tcf1 in β cells of the islet.  Mice with targeted 
disruption of Tcf1 (Tcf1-/-) develop a diabetic phenotype, however, also suffer 
from Laron dwarfism and multiple organ manifestations such as renal 
dysfunction with glucosuria, pathological liver tests, and hepatomegaly 
(Pontoglio et al., 1996; Lee et al., 1998).  MODY3 carriers may display glucosuria, 
however, liver function is usually not affected (Stride et al., 2005).  Another 
experimental model for MODY3 has been generated by expression of a transgene 
carrying the dominant negative P291fsinsC mutation in β cells of mice.  These 
mice develop progressive hyperglycemia due to impaired glucose-stimulated 
insulin secretion (Hagenfeldt-Johansson et al., 2001; Yamagata et al., 2002).  
 17
Studies in islets of MODY3 models showed that Tcf1 regulates a variety of 
genes encoding proteins important for glucose transport, glycolysis, and 
mitochondrial metabolism.  Specifically, Tcf1 can activate promoters of the 
glucose transporter type 2 (Slc2a2, Glut2), which facilitates glucose transport into 
β cells and L-type pyruvate kinase (PKL), which is a rate-limiting enzyme of 
glycolysis (Wang et al., 1998; Yamagata et al., 2002).  Other genes that are 
regulated by Tcf1 include aldolase B, insulin, and the mitochondrial 2-oxo-
glutarate dehydrogenase (OGDH) E1 subunit (Wang et al., 1998; Wang et al., 
2000).    
Pancreatic islets of both Tcf1-/- and transgenic mice are small and irregular 
in shape.   Transgenic mice, in particular, display abnormal islet architecture, 
which may be due to decreased expression of E-cadherin seen in these islets 
(Yamagata et al., 2002).  E-cadherin is an adhesion molecule that is critical for 
cell-cell interaction.  Both mice exhibit a progressive reduction in β cell number, 
proliferation rate, and pancreatic insulin content.  Studies showed that Tcf1 can 
influence the expression of genes involved in cell proliferation and apoptosis 
such as IGF-1, cyclin E, p27KIP1 and Bcl-xL as well as transcription factors 
important for β cell development and function such as Pdx-1, HNF4α, and 
NeuroD (Yang et al., 2002; Wobser et al., 2002; Shih et al., 2001).  These data 
indicate that Tcf1 target genes are required for maintenance of normal β cell 
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mass; however, exact molecular pathways involved in this regulation remain 
elusive. 
 
1.6 Identification of a Tcf1 target gene involved in β cell growth 
 In order to identify genes that are important for regulation of β cell mass, 
an Affymetrix microarray experiment was done to compare gene expression 
profiles of islets isolated from Tcf1-/- mice and their wild-type littermates.  This 
analysis led to the identification of a transcript encoding transmembrane protein 
27 (Tmem27) that is markedly reduced in the islets of Tcf1-/- mice.   
Tmem27 is a 222 amino acid type 1a transmembrane protein that contains 
a signal peptide, an extracellular domain, and a transmembrane domain 
followed by a cytoplasmic tail.  Tmem27 is highly homologous among human, 
rat, and mouse.  Among the three species, Tmem27 shares 84.3% identity in 
nucleotide sequence and 81.9% homology in amino acid sequence.  Tmem27 was 
initially termed collectrin as it has been localized to the luminal surface and 
cytoplasm of collecting ducts and was originally described as a kidney-specific 
gene that is upregulated in an injury-induced renal hypertrophy model (Zhang 
et al., 2001).  In the only published account of Tmem27, Zhang et al. had noted 
the protein as a homolog of angiotensin-converting enzyme-related 
carboxypeptidase (ACE2) as it shares 47.8% identity with non-catalytic 
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extracellular, transmembrane, and cytosolic domains of ACE2.  Moreover, 
Tmem27 expression was described during mouse kidney development.  Tmem27 
is detectable at E13 in the ureteric bud branches.  Its expression is progressively 
increased in later stages of gestation extending into the neonatal periods and 
then is decreased in adult life (Zhang et al., 2001). 
In this thesis, I describe the specific expression of Tmem27 in β cells of the 
endocrine pancreas.  I carried out a comprehensive biochemical and functional 
analysis of Tmem27 and demonstrated that it is a stimulator if β cell replication 






















2.1. Tmem27 expression is regulated by Tcf1 
In an attempt to identify mitogenic factors in pancreatic β cells, we 
compared gene expression in isolated pancreatic islets of Tcf1–/– and wildtype 
littermates using Affymetrix™ oligonucleotide expression arrays. This analysis 
identified a gene encoding a transmembrane-spanning protein (Tmem27) that 
showed a 16-fold decrease in expression levels of Tcf1–/– mice compared to 
controls. This result was confirmed by RT-PCR in an independent group of 
animals (Figure 4). To study whether Tcf1 is a direct activator of Tmem27 
transcription, I analyzed the Tmem27 promoter and identified two putative Tcf1 
binding sites in its regulatory region that were conserved between human and 
mouse (Figure 5). I cloned an 815 bp promoter region upstream of a luciferase 
reporter gene and co-expressed it with a Tcf1 expression vector. Transient co-
transfection of Tcf1 and Tmem27 promoter led to a >7-fold activation of 
luciferase activity (Figure 6).       
  
Figure 4. Tmem27 expression is decreased in the islets of
Tcf1–/– mice compared to wildtype littermate controls.
Expression levels were measured with RT-PCR, GAPDH
was used as a control. C: no DNA added; –RT: no reverse
transcriptase added to reaction. 
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 Tcf binding sites are boxed in blue.  A second site (red box) denotes a putative Pdx-1 binding site. 
Highlighted sequences (green) indicate positions of the mutated Tcf binding sites. 
 
When each Tcf1 site in the Tmem27 promoter was selectively mutated, 
transcriptional activation was reduced 70-80% (Figure 6). To demonstrate 
binding of Tcf1 to these sites in vitro I carried out electrophoretic gel mobility 
shift assays (EMSA) using double stranded 32P-labeled oligonucleotides 
containing the respective Tcf binding sites and MIN6 cell extracts. Figure 7 
shows that the probe shifted upon addition of nuclear extracts and that the site of 
the farnesoid X receptor promoter (Fxr)(Shih et al, 2001a). The specificity of 
protein binding to these sites was also determined by further shifting the DNA-
Tcf1 complex using a specific anti-Tcf1 antiserum (Figure 7). I also investigated if 
Tcf1 directly increases the expression of Tmem27 by performing chromatin 
immunoprecipitation assays (ChIP). Tcf1 bound to the binding sites in the 
Tmem27 promoter of MIN6 cells and pancreatic islets but not in primary 
hepatocytes where Tmem27 is not expressed (Figure 8). These data confirm the 
Figure 5. Promoter analysis predicted two 
conserved Tcf binding sites in the upstream 
regulatory regions of human and mouse (bottom) 
Tmem27 genes, at  – 60 and – 117 base pairs relative 
to the transcriptional start site.  Human (top) and 
mouse (bottom) promoter sequences are aligned and
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binding could be competed by adding increasing amounts of a known binding 
functionality of the Tcf1 binding sites in vivo and demonstrate that Tcf1 is 
required for expression of Tmem27 in pancreatic β cells.   
                            
                                                                  
 
Figure 6. Transcriptional activation assays in HepG2
cells that were transfected with pcDNA3 or pTcf1,
pCMV-β-glactosidase, and the luciferase reporter gene
using a 815 bp Tmem27 mouse promoter (left panel).  Tcf
binding sites were mutated individually in the promoter
sequence of the reporter vector and MIN6 cells were
transfected with vectors pT27luc-wt, pT27luc-m1 or
p27luc-m2. Luciferase activity was normalized to β-
galactosidase activity (right panel).  Each value
represents the mean of eight independent experiments. *:
P < 0.05, **: P < 0.01, ***: P < 0.001. 
Figure 7. EMSA analysis using oligonucleotides
for Tcf binding sites 1 and 2 and whole cell
extracts of MIN6 cells. Competitor represents
unlabeled double-stranded oligonucleotides at
increasing concentrations containing Tcf1
binding site of Fxr-1 promoter (Shih et al., 2001).
The signal of the free probe at the bottom of the
gel was cut off. 
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could not be found in primary hepatocytes, which do not express Tmem27. ChIP for Tcf1 was validated in 
primary hepatocytes by amplification of a region in apolipoprotein M (apoM) promoter that spans the Tcf1 
binding site (Richter et al., 2003). 
 
2.2. Pdx-1 binds to a conserved site in Tmem27 promoter  
 The promoter analysis of Tmem27 also revealed a conserved binding site 
for the β cell specific transcription factor Pdx-1.  This binding site is embedded in 
a Tcf1 binding site, termed “site 2” in figure 5.  Co-expression of Pdx-1 with 
Tmem27 promoter cloned upstream of the luciferase reporter gene led to a 
significant increase in luciferase activity compared to co-transfection with empty 
expression vector (Figure 9).  EMSA in MIN6 cell extracts showed that 32P-
labelled probe for site 2, but not site 1, formed DNA/Pdx1 complexes upon 
addition of the extracts and this interaction can be further shifted with the 
addition of an anti-Pdx-1 antibody (Figure 7).    
 
 
Figure 8. Chromatin immunoprecipitation assays in pancreatic 
islets and MIN6 cells demonstrate an in vivo interaction of Tcf1 
with the promoter of Tmem27. A 150 bp region spanning
binding sites 1 and 2 was amplified with PCR.  This interaction
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2.3. TMEM27 is regulated during pancreas development 
Expression of Tmem27 was studied during mouse pancreatic 
development by immunohistochemical staining.  In newborn and adult pancreas, 
Tmem27 expression is restricted to β cells of the islet (Figure 3A). During 
development of the pancreas, Tmem27 is expressed at the earliest time when 
hormone positive (mainly glucagon-positive cells) are apparent. At embryonic 
days E10.5 and E12.5 Tmem27 expression is localized in cells that express 
glucagon and insulin. During the period of endocrine cell expansion, from 
embryonic day 13.5 to 18.5, Tmem27 mainly co-localizes with glucagon until 
right before birth at E18.5 when it is also detected in insulin positive cells (Figure 
10).  Tmem27 expression throughout development is specifically localized to 
hormone-positive cells.  At E15.5 in the mouse, Ngn3 expression peaks and 
marks the endocrine precursor cells.  These cells do not express any of the 
endocrine hormones and subsequently, Tmem27 expression does not co-localize 
with Ngn3 (Figure 10).  
Figure 9. Transcriptional activation assay in HepG2 cells
that were transfected with pcDNA3, pPdx1 or pTcf1,
pCMV-β-glactosidase, and pT27luc-wt.  *: P < 0.05, ***: P
< 0.001. 
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Figure 10. Tmem27 is expressed in the developing mouse pancreas
Immunofluorescence of paraffin embedded pancreatic tissue from denoted time points in the mouse
development with α-Tmem27C, α-Insulin and α-Glucagon antibodies. Developmental stages are 
indicated as embryonic (E) days. 
 Immunofluorescence with α-Tmem27C and α-Ngn3 in consecutive sections of E15.5 pancreas. 
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2.4. Tmem27 is an N-linked glycoprotein and forms dimers in vivo 
Tmem27 contains two predicted N-glycosylation sites at amino acid 
residues 76 and 93, respectively. MIN6 cells were treated with tunicamycin, an 
inhibitor of N-glycosylation (Waechter and Lennarz, 1976).  Cells were incubated 
in the presence of increasing concentrations of tunicamycin and protein extracts 
were prepared and analyzed by SDS-PAGE and immunoblotting. Two bands 
with increased electrophoretic mobility appeared upon treatment with 
tunicamycin, whereas the high molecular weight protein disappeared (Figure 
11). This result was confirmed with an in vitro assay using N-glycanase, an 
enzyme that releases intact N-linked glycans (Figure 11). These data suggest that 
Tmem27 is an N-linked glycoprotein. 
I also carried out chemical cross-linking experiments to test if Tmem27 
protein exists as a multimer.  MIN6 cell extracts were incubated in the presence 
of two different cross-linking reagents: BMH (bismaleimidohexane), a 
membrane-permeable, non-cleavable compound and DTBP (dimethyl 3, 3’-
dithiobispropionimidate), a membrane permeable, cleavable compound. 
Following these treatments, an SDS-PAGE analysis was performed under 
reducing and non-reducing conditions (Partis et al., 1983; Geisler et al. 1992). 
Non-reducing western blots revealed a band of exactly twice the molecular 
weight than under reducing conditions.  Cell extracts treated with BMH showed 
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the dimer protein in both reducing and non-reducing blots. In contrast, the 
protein dimers disappeared under reducing conditions in the presence of DTBP 
(Figure 12). The results were similar in MIN6 cells that endogenously express 
Tmem27 and in N2A cells that were transiently transfected with Tmem27 
expression vector (Figure 12).                                                         
                              
 
 






Figure 11. MIN6 cells were incubated with increasing amounts of tunicamycin, which inhibits
glycosylation at asparagine residues.  Addition of DMSO alone to the cells had no effect. 
Figure 12. MIN6 cell lysates were incubated with either PBS, or cross-linking reagents dimethyl 
3, 3’-dithiobispropionimidate (DTBP) and bismaleimidohexane (BMH).  SDS-PAGE under non-
reducing conditions and immunoblotting using anti-Tmem27C antibodies showed a band twice 
the molecular weight of full-length Tmem27.  Under reducing conditions, only the monomer
was detected in PBS and DTBP-treated cell lysates.  In contrast, the dimer persisted in BMH-
treated samples as BMH cross-linking could not be reversed.  
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2.5. Tmem27 is cleaved and shed from pancreatic β cells 
Tmem27 has previously been predicted to be a transmembrane protein 
with an N-terminal extracellular domain (Zhang et al., 2001). We generated two 
antibodies (α-Tmem27N and α-Tmem27C) that recognize peptides from extra- 
and intracellular domains of the protein, respectively (Figure 13).  In Western 
blotting experiments α-Tmem27C detected two bands in whole cell lysates of 
MIN6 cells (Figure 14).  The higher molecular weight band corresponded to the 
predicted molecular weight of the glycosylated full-length protein.  The lower 
band (≈25 kD) was also specific since it could be detected by Western blotting in 
cell lysates following transfection with a vector (p-Tmem27.V5) expressing a C-
terminal V5-Tag fusion protein and an anti-V5 antibody (Figure 14).  
 






Figure 13. Schematic drawing of TMEM protein domains, including regions against which
antipeptide antibodies were raised and epitopes were inserted. Numbers denote positions of amino
acid residues. S: Signal peptide sequence; TM: transmembrane domain; N-Gly: N-glycosylation 
sites; HA: position of HA-epitope insertion; V5: position of V5-epitope insertion; Tmem27N and 
Tmem27C indicate positions of sequences used for antipeptide antibody production. 
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cell lysates from above were probed with α-V5 antibody (right panel).  The antibody against the V5-epitope 
also detected both bands in pTmem27.V5 transfected cells but not in pcDNA3 transfected cells. 
 
I hypothesized that Tmem27 might be cleaved and possibly shed, with the 
lower molecular weight band representing the C-terminal transmembrane 
spanning part of Tmem27. I therefore analyzed supernatants from different cell 
lines (including neuronal N2A cells, HepG2 cells, HEK293 and M-1 cells that 
were derived from collecting ducts of the kidney and which exhibit endogenous 
expression of Tmem27). Cells were cultured for 48 h in reduced serum medium 
and Tmem27 immunoreactivity in the supernatant was assayed by Western 
blotting using α-Tmem27N. I detected a band corresponding to a ≈25kDa protein 
in clonal β cell lines MIN6 and INS1E (Figure 15). Interestingly, this protein can 
only be detected in the supernatant but not in whole-cell lysates, indicating that 
cleavage occurs at the outer plasma membrane. This cleaved form of Tmem27 
could also be detected in media incubated with isolated mouse pancreatic islets                            
 
Figure 14. Anti-Tmem27C antibody in Western blots of 
MIN6 cells detected two bands for Tmem27 (left panel). 
The 25 kDa band became more abundant in cells that 
were transfected with pTmem27.V5.  Immunoblots of 
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(Figure 16). Treatment of supernatants with N-Glycanase led to the 
disappearance of the ≈25kDa protein and the emergence of a band at ≈12kDa, the 
expected molecular weight of the unglycosylated N-terminal domain of Tmem27 
(Figure 17). Interestingly, in spite of robust expression of full-length protein in 
cell-lysates, I failed to detect this band in Western blot analysis in the culture 








Figure 15. Denoted cell lines were transfected with pcDNA3 or pTmem27 and full length protein
was detected with anti-Tmem27C in Western blots of cell lysates. Secreted protein was detected
with anti-Tmem27N only in the supernatant of MIN6 cells. Increased expression of full-length 
protein led to increased amounts of secreted protein solely in the β cell lines (MIN6 and INS1E). 
Supernatants were normalized to protein content of cell lysates. 
Figure 16. Mouse pancreatic islets were isolated and incubated for 72 hrs. Supernatants were
collected and islets were transferred in lysis buffer. Full-length protein was detected with anti-
Tmem27C in Western blots of lysates and secreted protein was detected with anti- anti-Tmem27N in 







 expression vector (pTmem27). In contrast, over-expression of Tmem27 in MIN6 
and INS1E cells led to increased amounts of secreted protein in their culture 
media (Figure 15). I also showed that siRNA-mediated reduction in Tmem27 
protein levels correlated with decreased levels of the secreted form of Tmem27 in 






Supernatants from the same cells and reductions in the levels of secreted proteins were detected with anti-
Tmem27N. Supernatants were normalized to protein content of cell lysates. 
 
 Lastly, in order to irrefutably prove that N-terminal portion of Tmem27 is 
cleaved and secreted from β cells an expression vector (pTmem27-HA) was 
generated in which a nine amino acid HA-epitope tag was inserted downstream 
Figure 17. Supernatant from MIN6 cells was incubated with N-
glycanase.  The molecular weight shift in the Western blot indicates 
that the enzyme removed sugar moieties from secreted Tmem27.
Secreted protein was detected with anti-Tmem27N antibody. 
 
 
Figure 18. MIN6 cells were electroporated with siRNAs 
targeting GFP or Tmem27. In the cells that were 
electroporated with si-Tmem27#1 and #2, reduction in the 
levels of Tmem27 protein was detected with anti-Tmem27C 
48 hrs after electroporation. SDS-PAGE was run with 
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of acid residues 39 of the Tmem27 protein (Figure 13).  MIN6 cells transfected 
with this vector secreted a protein in the supernatants that could be detected 
with an anti-HA antibody and had a similar size as untagged Tmem27. This 
protein was not detected in control cells or cells expressing the untagged protein 
(Figure 19). Together, these data demonstrate that Tmem27 is a pancreatic β cell-















Figure 19. MIN6 cells were electroporated with pcDNA3, pTmem27 or pTmem27-HA.  Overexpression 
of Tmem27 was detected by Western blotting of cell lysates with anti-Tmem27C antibodies. 
Supernatants from the same cells were subjected to Western blotting with anti-HA epitope antibody. 
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2.6. Tmem27 is a constitutively shed plasma membrane protein  
 To localize Tmem27 in pancreatic β cells, I performed 
immunofluorescence studies using anti-Tmem27N and –C antibodies. MIN6 or 
dispersed pancreatic islets were grown on slides, fixed and permeabilized and 
treated with primary antibodies raised against insulin and synaptophysin (Syn), 
specific markers for insulin-containing dense-core granules and synaptic-like 
microvesicles, respectively (Wiedenmann et al., 1988). Neither insulin nor 
synaptophysin co-localized with Tmem27, demonstrating that Tmem27 is not a 
constituent of these organelles (Figure 20).  
                          




Figure 20. Isolated mouse islets were dispersed and stained with anti-Tmem27C and anti-
Insulin, anti-Synaptophysin or anti-Glut-2 antibodies. 
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Subcellular fractionation of MIN6 cells with a sucrose density gradient also 
showed that Tmem27 was not in the same vesicles as insulin or prohormone 
convertase 1/3 (PC1/3), a protease that cleaves insulin and resides in the dense 
core vesicles with insulin.  Tmem27 appears to localize to similar-sized vesicles 
as synaptic-like microvesicles as immunoreactivity was detected in the same 
samples with Syn (Figure 21).   




Specific staining of Tmem27 was detected in the perinuclear compartment and 
on the plasma membrane. Plasma membrane staining of Tmem27 co-localized 
with membrane immunoreactivity of Glut2, further supporting that Tmem27 is a 
surface-membrane protein (Figure 20). We also studied Tmem27 by electron 
Figure 21.  MIN6 cells were fractionated in a linear sucrose density gradient.  Insulin levels
were measured using a radioimmunoassay (RIA) for rat insulin.  All fractions were subjected to
SDS-PAGE and immunoblotted with α-Syn, α-Tmem27C, and α-PC1/3. 
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microscopy and observed nanogold particles associated with the plasma 
membrane in proximity to vesicle /membrane fusion events (Figure 22).  
 





To further investigate the release of the cleaved form of Tmem27 I stimulated 
isolated pancreatic islets cells with low (2.8 mM) and high (11.1 mM) glucose 
concentrations. Whereas insulin secretion increased when stimulated with 
glucose I did not measure a change in Tmem27 concentrations in the supernatant 
of these cells (Figure 23). I repeated the experiment in MIN6 cells by incubating 
the cells in media with low (5.5 mM) and high (25 mM) levels of glucose and 
observed that Tmem27 shedding did not follow insulin secretion dynamics 
(Figure 24).   
Figure 22.  Electron microscopy performed on MIN6 cells with anti-Tmem27C antibodies localized 
Tmem27 in small secretory vesicles (arrows).  IgG conjugated to 10 nm gold particles was used for
detection of the antibody.   (Right Panel) vesicles that contain Tmem27 were detected during fusion







Figure 23. An equal number of size-matched mouse islets were incubated in either 2.8 mM or 11.1 mM 
glucose. Supernatants were collected after 72 h and soluble Tmem27 levels were quantified and normalized 
to protein content of islet lysates. Secreted insulin levels were measured after 6 h incubation in the same 




Lastly, I performed pulse-chase experiments using 35S-methionine to determine 
the kinetics of uncleaved and soluble Tmem27 proteins. [35S]methionine 
incorporation in Tmem27 was calculated from band densities on scanned 
autoradiography films.  Relative immunoprecipitated radioactivity on the gels 
showed that [35S]methionine was incorporated in Tmem27 protein for up to 3 


















Glucose [mM]    2.8         11.1
Figure 24.  MIN6 cells are incubated in 5.5 mM or
25 mM glucose.  Supernatants were collected
after 6 hrs and immunoblotted with α-Tmem27N.
Cell lysates were also collected to detect full-
length protein with α-Tmem27C.  Protein content
of wells were assessed with α-Tbp antibody. 
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incorporation (Figure 25).  The half-life of Tmem27 from linear regression 
analysis of the data points was determined to be ≈27 hours.  [35S]-labeled of 
soluble Tmem27 was immunoprecipitated from MIN6 supernatants and 
quantitated by scintillation counting after PAGE.  Relative radioactivity present 
in the bands over a period of 24 hours revealed that the amount of cleaved 
Tmem27 in the supernatant of MIN6 cells increased linearly and by 
approximately 10% every hour. These data show that soluble Tmem27 is shed 






   
 
Figure 25.  [35S]Methionine incorporation into Tmem27 was measured in MIN6 cells during a pulse-chase 
























2.7. Search for a cleavage site and protease 
 In order to further characterize the shedding of soluble Tmem27, I 
attempted to determine the exact site of cleavage by mass spectrometry.  I ran 
immunoprecipitated protein from MIN6 supernatants on SDS-PAGE (Figure 26) 
and excised the band for amino acid sequence determination.  This method was 
unsuccessful most likely because glycosylation on the protein hinders the 
process.   
               
 
Interestingly ectodomain shedding of Tmem27 is a very β cell specific 
event.  Initially this observation led to the hypothesis that the protease 
responsible for the generation of soluble Tmem27 is a β cell-specific or –enriched 
enzyme.  Analysis of the amino acid sequence revealed a putative conserved 
proprotein convertase cleavage site at residues 106-111 (RXXR/KXR) (Figure 27).  
The major endoproteolytic processing enzymes of endocrine cell secretory 
pathway are the subtilisin-like proprotein convertases.  In the β cell, members of 
this family such as furin, prohormone convertase 1/3 (PC1/3) and prohormone 
Figure 26.  Immunoprecipitated Tmem27 from
supernatants of MIN6 cells was detected with
Coommassie blue.  Rabbit IgG was used as a
control. 
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convertase 2 (PC2) function in cleavage of insulin and other peptides (Steiner, 
1998).  Functionality of the cleavage site was investigated by PCR site-directed 
mutagenesis.  Depending on the particular site arginines and/or lysines are the 
key residues in proprotein convertase cleavage.  Therefore, I generated two 
mutated versions of pTmem27.V5.  Arginine at 106 and lysine at 109 were 
mutated to isoleucine and alanine, respectively in one expression vector (pT27-
R106K109) and the arginine at position 111 was changed to a leucine in a second 
expression vector (pT27-R111).  The mutated versions of Tmem27 migrated 
differently compared to wild-type Tmem27 on SDS-PAGE (Figure 27).  However, 
the protein was cleaved successfully as increased soluble form was detected in 
the supernatants of all MIN6 cells and on western blots using α-Tmem27N, the 
lysates showed both the full-length form and the C-terminal fragment left upon 
cleavage (Figure 27).  In order to exclude the involvement of the known β cell 
proprotein convertases as well as that of carboxypeptidase E (exopeptidase 
necessary for efficient endoproteolytic processing of proinsulin and several other 
protein precursors) in Tmem27 shedding, siRNAs were used to reduce the 
expression of these proteases in MIN6 cells.  Reduced expression of furin, PC1/3, 
PC2 or carboxypeptidase E in MIN6 cells did not have an effect on the levels of 
soluble Tmem27 in the supernatant of these cells (data not shown).  These 
findings were also supported by data in results section 2.6 where Tmem27 was 
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localized to vesicles separate from insulin containing secretory granules where 




 Various non-β cell lines were tested for Tmem27 shedding with negative 
results.  Examination of the data from Affymetrix™ array of Tcf1–/– islets revealed 
regulation of hepatocyte growth factor activator (HGFA) expression.  Expression 
levels of HGFA was markedly reduced in the islets of Tcf1–/– mice compared to 
wild-type controls.  Two experiments were performed to investigate the 
possibility of a role HGFA might play in Tmem27 cleavage. First, isolated 
primary hepatocytes were infected with an adenovirus expressing the human 
Tmem27 protein (Adv-hTmem27).  Supernatants were run on SDS-PAGE and 
blotted with α-Tmem27N to detect soluble protein.  Figure 28 shows that even 
though a high level of Tmem27 expression was achieved in isolated hepatocytes, 
Figure 27.  There is a putative prohormone
convertase site in both human and mouse
Tmem27 sequence.  The important residues for
cleavage are highlighted in red.  The denoted
sequences are mutated on pTmem27 expression
vector. 
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no protein shedding occurred in the supernatants 48hrs after infection.  Secondly, 
neither over-expression of HGFA protein nor reduction of its expression with 
several siRNAs had any effect on the levels of soluble Tmem27 in the 
supernatants of MIN6 cells (data not shown). 
 
        
 
 The possibility of the protease that cleaves Tmem27 being a soluble 
enzyme in MIN6 supernatant was explored by co-culture studies of MIN6 and 
COS7 cells.  COS7 cells were transfected with either pcDNA3 or pTmem27-HA 
and seeded in 6 well plates.  MIN6 cells were plated in cell culture inserts on top 
of the COS7 cells and incubation was continued for 48 hours.  Supernatants were 
immunoblotted with α-HA antibody and α-Tmem27N to detect the released 
protein from either cell type.  Figure 29 shows that soluble protein from MIN6 
cells could be detected in COS7 supernatant demonstrating that co-culture 
system was functional, however, no HA tagged protein could be detected as 
MIN6 supernatant was not able to induce release of Tmem27 from COS7 cells.  
  
Figure 28.  Isolated primary hepatocytes are
infected with either increasing amounts of Adv-
hTmem27 or Adv-GFP at 1:200 dilution.  Cells
were incubated in OPTI-MEM for 48 hrs and




Ectodomain shedding is an important regulatory mechanism in the 
function of membrane-bound cell-surface molecules (Arribas and Borroto, 2002) 
and the most widely studied inducer of shedding is phorbol 12-myristate 13-
acetate (PMA), which activates protein kinase C (Schlondorff and Blobel, 1999).  
Upon incubation of MIN6 cells with PMA, shedding of Tmem27 was also 
stimulated.  MIN6 cells were incubated in either 1 µM PMA or DMSO in OPTI-
MEM for 1.5 hours and Figure 30 shows that cells, that were stimulated with 
PMA, had significantly more soluble Tmem27 in the media.  Upon this finding, I 
investigated whether other cell types that do not endogenously express Tmem27 
would be able to shed the ectodomain with PMA stimulation.  COS7 cells were 
transfected with pTmem27.V5 and 48 hours later they were stimulated with 
PMA for 6 hours.  The supernatant from PMA and DMSO treated cells were 
immunoblotted with α-Tmem27N.  PMA stimulated COS7-pTmem27.V5 showed 
Figure 29.  COS7 cells were transfected with either 
pcDNA3 or pTmem27-HA and co-cultured with 
MIN6 cells that were electroporated with 
pcDNA3 or pTmem27.V5.  Top legend shows 
overexpression of Tmem27 in COS7 and MIN6 
cells.  Bottom legend denotes two layers of the co-
culture setup. 
 43
no bands at 25 kDa where soluble Tmem27 migrates compared to DMSO treated 
COS7-pTmem27.V5 (Figure 30). 
                                       
                 Figure 30.  Stimulation of ectodomain shedding in MIN6 and COS7 cells with PMA.   
 
 Next a selective screening approach was taken to possibly identify the 
type of protease involved in the release of soluble Tmem27.  MIN6 cells were 
incubated in OPTI-MEM with various protease inhibitors at different 
concentrations for 3hr, 6hr, and 12hr periods.  Table 2 displays the different 
protease inhibitors used as well as their specificity for protease inhibition.  As 
seen in Figure 31 and 32, none of the protease inhibitors had an effect on the 




Figure 31.  MIN6 cells were incubated in 
OPTI-MEM supplemented with denoted 
protease inhibitors for 3hours and 
supernatants were immunoblotted with 
α-Tmem27N. 
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 Remarkably, BB94 was also able to inhibit stimulation of Tmem27 
shedding by PMA (Figure 32).  BB94 (batimastat) is a hydroxamate-based 
competitive inhibitor and has been shown to inhibit activity of many 
metalloprotease disintegrins (ADAM family of proteases) and certain ADAMs 
have been shown to be mediators of PMA stimulated ectodomain shedding 
(Black et al., 1997).  Three members of this family, ADAM9, ADAM10 and 
Inhibitor Substrates Working 
Concentration 
Pefabloc Broad serine protease inhibitor 0.1 mg/ml 
Aprotinin Serine protease inhibitor  0.01-3 µg/ml 
Leupeptin Serine and cysteine protease inhibitor 10-100 µM 
PMSF Serine and cysteine protease inhibitor 0.1-1 µM 
E64d Cysteine protease inhibitor 10 µM 
Phosphoramidon Inhibitor of metalloendopeptidases 100 µM 
BB94 Metalloprotease inhibitor 1 µM 
Figure 32.  MIN6 cells were incubated in 
OPTI-MEM supplemented with DMSO 
or 1 µM PMA for 1.5 hrs for stimulation 
of ectodomain shedding.  For inhibitor 
experiment, MIN6 cells were either 
incubated with 1 µM BB94 alone or 1 µM 
PMA and 1 µM BB94 for 1.5 hrs. 
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ADAM17, have been studied in the mouse pancreas and display specific 
developmental and adult expression patterns (Asayesh et al., 2005).  ADAM9 
expression gets restricted to β cells in adult mouse pancreas.  Two approaches 
were taken to see whether ADAM9 is involved in Tmem27 cleavage.  SiRNA 
targeted reduction in ADAM9 expression in MIN6 cells had no effect on soluble 
Tmem27 generation (data not shown).  Moreover, islets isolated from ADAM 9-/-
15-/-12-/- triple knockout (Sahin et al., 2004) mice release similar amounts of 
Tmem27 in their supernatants as islets isolated from wild-type control mice 
(Figure 33). 
                                
Figure 33.  Isolated islets from ADAM 9-/-15-/-12-/- and control animals were incubated for 48 hrs in OPTI-









2.8. Tmem27 influences insulin secretion 
 Glucose stimulated insulin secretion was measured in MIN6 cells with 
increased and reduced Tmem27 expression.  MIN6 cell were transfected with 
either pcDNA3 or pTmem27.V5.  MIN6 cells were stimulated with glucose or 
KCl 48 hours post transfection and insulin released into the media was 
measured.  Increased expression of Tmem27 significantly reduced insulin release 
from MIN6 cells (Figure 34).  In parallel, reducing expression of Tmem27 with 
siRNAs led to a significant increase in glucose stimulated insulin secretion 
(Figure 35).  Increased and reduced expression of Tmem27 had no effect on the 
insulin content of MIN6 cells (Figure 36).  
 
   
Figure 34.  Glucose- (2.8 mM or 25 mM) and KCl (60mM)-stimulated insulin secretion in MIN6 cells 48 






A recent paper also described a role for Tmem27 in insulin secretion 
(Fukui et al., 2005).  The authors proposed that full-length Tmem27 augments 
insulin secretion in INS1 cells.  They postulated a function for Tmem27 in insulin 
exocytosis through its interaction with a SNARE complex component called 
snapin.  Fukui et al. further showed immunoprecipitation data that associated 
Tmem27 with other SNARE complex proteins such as SNAP25 and VAMP2.  
Since the aforementioned data contradicted my findings in Figure 34 and 35, I 
attempted to reproduce some of the experiments.  Tmem27 was 
immunoprecipitated with α-Tmem27C from MIN6 cell lysates.  The eluate as 
Figure 35.  Glucose-stimulated insulin 
secretion in MIN6 cells that were transfected 
with a siRNA against luciferase (si-Luc) or si-
Tmem27.   ***: P < 0.001. 
Figure 36.  Insulin content of MIN6 cells was 
measured by acid/ethanol extraction and 
normalized per protein content of each 
sample.  There was no significant difference 
in insulin content of MIN6 cells transfected 
with pcDNA3 or pTmem27. 
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well as flow-through and the wash fractions of the experiment were subjected to 
SDS-PAGE and detected with α-Tmem27C.  Rabbit IgG was used as a control 
since Tmem27 antibody was raised in rabbits.  The western blot in Figure 37 
showed that Tmem27 was successfully immunoprecipitated with α-Tmem27C 
and could also be detected in the flow-through fraction of the rabbit IgG 
experiment.  The western blots for the same fractions using α-snapin and α-
VAMP2 antibodies showed that these proteins did not precipitate with Tmem27 
in MIN6 cells (Figure 37).  Furthermore, Tmem27 did not co-localize with either 
VAMP2 or syntaxin by immunofluorescence on isolated and dispersed 




Figure 37. Immunoprecipitation of
Tmem27 in MIN6 cells with α-
Tmem27C.  F-T: Flow-through. 
Figure 38. Immunofluorescence on
isolated primary islets with α-Tmem27C,
α-Syntaxin and  α-VAMP2.  No-
colocalization of Tmem27 was detected
with SNARE complex proteins. 
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2.9. Increased expression of TMEM27 in mouse models with islet hypertrophy 
and enhanced β cell replication in vitro 
I measured expression of Tmem27 in hypertrophied islets of ob/ob, db/db 
and aP2-Srebp-1c transgenic mice (Shimomura et al., 1998). Pancreatic islets from 
6-8 week old mice were isolated and gene expression levels were compared to 
their wild-type littermates. Using real-time PCR I found a 1.7, 1.7 and 2.7-fold 
increase in Tmem27 levels of ob/ob, db/db and aP2-Srebp-1c islets, respectively, 
compared to controls (Figure 39). In addition, islets isolated from these mice 
exhibited a significant increase in secretion of cleaved Tmem27 into the medium 











Figure 39. Tmem27 expression levels were measured in islets isolated from ob/ob, db/db, aP-Srebp-1c
and wildtype littermate control mice with quantitative RT-PCR. Tmem27 expression was evaluated 







Spontaneous mutant strain C57BL/KsJ db/db (BKS-Lepr/J) mice have the db 
mutation, a splicing mutation caused by a point mutation in the downstream 
intron of the leptin receptor gene, and are unresponsive to leptin. These mice 
have unrepressed eating behavior, become obese, and develop severe insulin 
resistance associated with hyperinsulinemia, hyperglycemia, and 
hypertriglyceridemia.  These mice show increased compensatory β cell mass up 
to 3 months of age, however, from 3 to 6 months they drastically reduce their β 
cell mass resulting in severe insufficiency of insulin secretion (Kawasaki et al., 
2005).  I compared the expression levels of Tmem27 in islets of BKS-Lepr/J mice 
and their littermate controls at 3 months and 6 months of age by real-time RT-
PCR.  Figure 41, left panel, shows that Tmem27 expression was markedly 
increased at 3 months when the islets of BKS-Lepr/J mice display hypertrophy.  
The right panel of figure 41 shows that at 6 months old the islets of BKS-Lepr/J 
mice had no difference in the expression levels of Tmem27 compared to their 
B
No. of 







Figure 40. Isolated islets from wildtype and 
ob/ob mice were matched for number and size 
and incubated in equal volumes of media for 72 
hrs.  Secreted protein was detected with anti-
Tmem27N. 
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littermate controls.  In this study, the Tmem27 expression levels were found to 
correlate with the islet mass of diabetic BKS-Lepr/J animals. 
           
Figure 41.  Tmem27 expression levels were measured in islets isolated from BKS-Lepr/J and wildtype 
littermate control mice with quantitative RT-PCR. Tmem27 expression was evaluated relative to β-actin 
levels in the same sample. **: P<0.01 
 
To study if Tmem27 stimulates pancreatic β cell replication I examined the 
effect of Tmem27 expression on the proliferation of MIN6 cells. Cells were 
electroporated with either siRNAs targeting Tmem27 or plasmid pTmem27. Cell 
replication was assessed by cell counting and measuring incorporation of 
[3H]thymidine 48 h after electroporation (Figure 42).  MIN6 cells that were 
transfected with pTmem27 exhibited ≈5-fold overexpression compared to 
pcDNA3 transfected cells and showed ≈2-fold increase in [3H]thymidine 
incorporation and increased cell density 48 h after plating.  In contrast, MIN6 
cells that had reduced expression of protein following siRNA treatment showed 
significantly lower [3H]thymidine incorporation and cell density (Figure 42). 
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Furthermore, I did not observe any changes in apoptosis in cells with increased 
or reduced expression of Tmem27 (Figure 43), suggesting Tmem27 it does not 
affect cell death.  
             
   
    
          
 
Figure 42. MIN6 cells were
electroporated with siRNAs targeting
luciferase or Tmem27 and pcDNA3 or
pTmem27. Cells were trypsinized 48 hrs
after electroporation, stained with trypan
blue and counted with a hemocytometer.
Each value represents a mean of six
independent experiments.  
Cell replication was measured by





To further elucidate if the full-length, truncated or soluble form of 
Tmem27 stimulated β cell replication in vitro I generated a Tmem27 mutant 
(pTmem27-V5.del.) in which amino-acid residues 17-129 were deleted. 
Transfection of pTmem27-V5.del. in MIN6 cells led to the expression of a 
truncated protein of ≈30kDa (Figure 44). [3H]thymidine incorporation assays 
demonstrated that expression of the full-length Tmem27 increased replication 
not only in MIN6 cells but also in HepG2 and HEK293 cells. In contrast, over-
expression of the truncated Tmem27 form showed no effect (Figure 45). I 
confirmed by immunofluorescence and cross-linking experiments that the 
truncated Tmem27 reached plasma membrane and was able to dimerize in MIN6 
cells (Figure 46).  Since non-β cell lines do not release the soluble Tmem27 form 
these data demonstrate that the full-length form of Tmem27 is responsible for the 
proliferation response. Independent evidence that the soluble form has no effect 
Figure 43. TUNEL assay was performed on
MIN6 cells that were electroporated with
siRNAs targeting luciferase or Tmem27 and
pcDNA3 or pTmem27. 
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on cell replication was obtained from co-culture and conditioned medium 
experiments in which cells were cultured with increasing concentrations of 
soluble Tmem27 (Figure 47 and 48). Together, these results demonstrate that the 
full-length form of Tmem27 stimulates cell proliferation in MIN6 and other cell 
types. 
 






Figure 44. MIN6 cells were 
electroporated with pcDNA3, 
pTmem27-V5, or pTmem27-V5del., 
which lacks amino acid residues 17-
129. The deletion mutant is expressed 
as a ≈30kDa protein. 
 
Figure 45. MIN6, HepG2 and HEH293 
cells were transfected with pcDNA3, 
pTmem27-V5 or pTmem27-V5.del. 
Cell replication was measured by 
[3H]thymidine incorporation. **: 
P<0.01. 
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Figure 46.  Immunofluorescence on MIN6 cells transfected with pTmem27-V5del showed that the deletion mutant 
localized to plasma membrane.  Cross-linking experiment showed that the deletion mutant formed dimers in MIN6 
cells. 
 





Figure 47. MIN6 cells were co-cultured 
with MIN6 cells electroporated with 
either pcDNA3 or pTmem27.  Cell 
replication of the bottom layer was 
measured by [3H]thymidine 
incorporation.   
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Figure 48.  HEK293 and MIN6 cells were incubated with conditioned media from MIN6 cells that expressed 
increasing amounts of Tmem27. Cell replication of the bottom layer was measured by [3H]thymidine 












2.10. Trangenic mice overexpressing Tmem27 in pancreatic islets exhibit islet 
hypertrophy 
 We generated two independent pancreatic β cell-specific transgenic lines 
following pronuclear microinjection of a vector construct in which the human 
Tmem27 cDNA is under the control of the rat insulin promoter. RT-PCR and 
immunoblot analysis showed that Tmem27 expression in both lines was ≈4-fold 
increased in pancreatic islets of transgenic mice compared to wildtype littermates 





I studied the islet mass at ages 10 and 20 weeks in transgenic animals by 
pancreatic islet morphometry. Transgenic mice exhibited normal islet 
morphology (based on immunohistochemistry using insulin/glucagon co-
staining) but had an approximately 1.5- and 2-fold increase in islet mass at 10 
and 20 weeks respectively, compared to wildtype littermates (Figure 50 and 51). 
No difference was found in the mass of non-β cells (α-, δ-, and PP-cells)(Figure 
52).  
Figure 49.  Increased expression of 
Tmem27 was detected with anti-Tmem27C 
in Western blots of islets isolated from both 
RIP-Tmem27 transgenic mice and wildtype 
littermate controls. 
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Figure 50.  Immunohistochemistry of whole pancreata from transgenic and control littermate mice (n = 3). 
Cross-sections were embedded in paraffin and stained for insulin using anti-insulin antibodies.  Images are 
representative of each genotype at 5x magnification. 
 
 
Figure 51.  Insulin staining in 7 µm sections was quantified using Metamorph software.  At least 50 islets 
were quantified for each pancreas in sections greater than 200 µm apart. *: P<0.05, **: P<0.01. 
 
The increase in β cell mass was further validated by measuring the total insulin 
content of transgenic and wild-type mice. The total insulin content was also 
significantly increased in transgenic mice over-expressing Tmem27 (Figure 53). 
To rule out that increased insulin resistance was responsible for the observed 
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increase in β cell mass I performed insulin-tolerance tests (ITT). No difference in 






Figure 52. Quantification of non-β cells of 
islets was performed by immunostaining 
with a cocktail consisting of anti-glucagon, 
somatostatin and pancreatic polypeptide 
antibodies. Analysis was carried out as in 
Fig. 51. 
 
Figure 53. Whole pancreata from 
transgenic and wild-type mice (n = 5) were 
isolated and homogenized in acid/ethanol. 
Insulin content was normalized per 





Figure 54.  Insulin tolerance test performed 
on transgenic and littermate control mice. 
N=6 per genotype.  Results were similar for 
both transgenic lines. 
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Furthermore, no significant difference in body weight, fasting insulin levels, 
plasma leptin concentrations and adiponectin levels were measured in transgenic 
mice compared control littermates (Figure 55). These data show that insulin 
resistance is not responsible for the increased β cell mass observed in the 
transgenic animals.  
                    
Figure 55.  Adiponectin, leptin , and fasting insulin levels in plasma were measured in both transgenic lines 
and their littermate controls.  Weight of transgenic mice along with controls were measured up to 6 months 
of age.  There was no difference in either the metabolic parameters or the weight gain. 
 
Increased β cell replication may lead to decreased glucose responsiveness due to 
dedifferentiation. Therefore, I performed glucose tolerance tests (IPGTT) and 
studied insulin secretion from islets that were isolated from either wild-type or 
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transgenic animals. Transgenic mice exhibited normal glucose tolerance (Figure 
56) and I observed a robust ≈13-fold increase in insulin secretion of islets isolated 
from transgenic mice in response to glucose stimulation, comparable to wild-
type controls (Figure 57). Together, these data demonstrate that Tmem27 
stimulates islet growth in vivo and that increased expression of Tmem27 does not 




              
Figure 57.  Insulin secretion of size-matched islets of transgenic mice and wild-type littermates in response 
to glucose and KCl. 
 
Figure 56. Intraperitoneal glucose tolerance 
test on transgenic and littermate control 
mice.  N=6 per genotype.  Results were 
similar for both transgenic lines. 
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 Transgenic animals and their littermate controls were challenged with a 
high fat diet.  Animals gained weight similarly and did not have a significant 
difference in fasting blood glucose levels.  However, transgenic animals 
performed better in IPGTT showing that overexpression of Tmem27 in β cells 







Figure 58. Transgenic mice and their 
littermate controls were fed a high fat diet 
over 16 weeks and their weight was 
monitored.  There was no significant 
difference in weight gain between both sets 
of mice.  N=6 per genotype. 
 
Intraperitoneal glucose tolerance test on 
transgenic and littermate control mice. 
Glucose levels were significantly lower in 




  In this thesis a genomic approach was used to identify genes that 
may contribute to islet mass maintenance during adult life and islet growth 
following increased demand for insulin secretion.  A number of transcription 
factors have been shown to be important regulators of both development and 
function of pancreatic β cells.  TCF1 is a transcription factor that leads to 
progressive early-onset diabetes called MODY3 when mutated in humans.     
Experimental mouse models for MODY3, Tcf1-/- and RIP-P291fsinsC, display 
decreased islet mass due to a progressive reduction in β cell number and 
proliferation rate.  Expression profiles of islets isolated from Tcf1-/- and wild-type 
littermate animals were compared in order to identify mitogenic factors that are 
regulated by Tcf1. 
 We found that Tmem27 exhibits markedly reduced expression in the islets 
of diabetic Tcf1-/- animals with decreased islet mass compared to wild-type 
littermates.  Further experiments revealed that Tmem27 is essential for optimal β 
cell growth in vitro and transgenic mice over-expressing Tmem27 exhibit 
increased islet mass.        
3.1 Tcf1 regulates expression of Tmem27 
 Promoter analysis and chromatin immunoprecipitation demonstrate that 
Tcf1 binds to conserved TCF1 binding sites in the Tmem27 promoter and that it 
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activates transcription of this gene. 
During the development of mouse kidney, Tmem27 is detectable at day 13 
of gestation in the ureteric bud branches. Its expression is progressively 
increased during later stages of the gestation extending into the neonatal periods 
and then is decreased in adult life (Zhang et al., 2001). Interestingly, we found 
normal levels of Tmem27 mRNA in the kidneys of Tcf1–/– animals (data not 
shown). Tcf1 expression in adult kidneys is restricted to the proximal and distal 
tubules, whereas Tcf2, a related protein that can form heterodimers with Tcf1 
and shares 93%, 75% and 47% sequence identity in their DNA binding domains, 
dimerization domains, carboxyl-terminal activation domains, respectively, is 
mainly localized in the collecting ducts (Rey-Campos et al., 1991; Coffinier et al., 
1999). Tmem27 is specifically expressed in the collecting tubules and therefore 
overlaps in its expression with Tcf2, indicating that Tcf2 homodimers may 
regulate the expression of Tmem27 in these cells in the adult kidney. In 
pancreatic islets of Tcf1–/– mice, Tmem27 expression is profoundly reduced, 
indicating that Tcf2 cannot substitute for Tcf1. This may be explained by 
different DNA binding specificities and/or by the higher Tcf1 expression levels 
compared to Tcf2 in pancreatic islets.  
3.2 Expression of Tmem27 in embryonic pancreas development  
 Tmem27 expression is found at the earliest stages of pancreatic 
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development (E10.5). Tmem27 is expressed in hormone-positive cells throughout 
development but becomes restricted to pancreatic β cells in the postnatal period. 
Tmem27 expression was not detected in Ngn3-positive neuroendocrine 
precursor cells. This expression pattern is reminiscent of the temporal and spacial 
expression of Pdx-1, an essential transcription factor for pancreas development, 
differentiation and insulin gene transcription (Jonsson et al., 1994; Offield et al., 
1996; Ahlgren et al., 1998). Indeed, a conserved binding site of Pdx-1 was 
identified in the Tmem27 promoter that partially overlaps with the Tcf1 site and 
which exhibits binding activity in EMSA analysis (Figures 7 and 9), suggesting 
that Pdx-1 may also be a critical regulator of Tmem27. These data make it 
tempting to speculate that the membrane–bound or secreted form of Tmem27 
contributes to the defect observed in Pdx-1 deficient mice, possibly by acting as a 
receptor or a signaling molecule (Johnsson et al., 2003).  
3.3 Ectodomain shedding of Tmem27  
I found that the N-terminal, extracellular domain of Tmem27 is cleaved 
and released from the plasma membrane of pancreatic β cells. Tmem27 does not 
co-localize with insulin granules or synaptic-like microvesicles, thereby ruling 
out the possibility that Tmem27 is released by the regulated secretory pathway. 
This is further supported by the observation that the cleaved protein cannot be 
detected in whole cell extracts of MIN6 cells and that release of the cleaved form 
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of Tmem27 is not regulated by glucose.  Interestingly, cleavage of Tmem27 only 
occurs in pancreatic β cells and could not be detected in cells that were 
transfected with a Tmem27 expression vector. This may suggest that Tmem27 is 
cleaved by a β cell-specific or -enriched protease. However, reducing the 
expression of proteases that have known β cell-specific actvity with siRNAs does 
not lead to any alterations in soluble Tmem27 levels.  Biochemical data as well as 
siRNA experiments exclude the involvement of furin, PC1/3, PC2 and 
carboxypeptidase E. 
 PMA stimulated shedding of Tmem27 as well as inhibition of this 
induction by the hydroxamate-based compound BB94 suggests the involvement 
of the zinc-dependent mettalloproteases of the metzincin family, which includes 
proteases containing a disintegrin and a mettaloprotease (ADAM) domain.  
ADAMs have been shown to cleave a variety of substrates with important roles 
in development and disease, including cytokines, growth factors/receptors and 
adhesion molecules.  In the pancreas, expression patterns are characterized for 
three members of this family.  ADAM9, 10, and 17 are all expressed in the 
pancreatic anlagen.  During development the expression of all three proteases 
gets restricted to different cell lineages.  In the adult pancreas ADAM9 is only 
expressed in β cells whereas ADAM17 is expressed in all endocrine cell types.  
ADAM10 is detected in endocrine as well as exocrine pancreas (Asayesh et al., 
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2005).  ADAM9-/- mice display no reduction in the release of soluble Tmem27 
release from isolated islets excluding the role of this protease in cleavage.  
ADAM17-/- mice are not viable, however, ADAM17∆Zn/∆Zn mice, which lack the 
Zn2+ binding domain, live for 2-3 weeks and can be used for islet studies. A 
recent study also identified ADAM17 as a mediator of the regulated ectodomain 
shedding of ACE2 (Lambert et al., 2005).  The cleavage site for ADAM17 
mediated proteolysis of ACE2 is not clear, however, it is predicted to be in the 
juxtamembrane stalk region from the mass of the released peptide.  The 
juxtamembrane regions of ACE2 and Tmem27 are highly homologous.  
Therefore, possible role of ADAM17 in Tmem27 shedding should be investigated 
with further studies in mice as well as with siRNA mediated targeting of 
ADAM17 expression in β cell lines. 
 Receptor shedding has been reported for members of diverse families of 
transmembrane receptors. For instance, the precursor form of hepatocyte growth 
factor is associated with the cell surface and biological function is dependent on 
proteolytic cleavage of an extracellular domain by the serine protease hepatocyte 
growth factor activator (HGFA)(Naldini et al., 1992; Miyazawa et al., 1993). Other 
receptors can bind to ligands upon cleavage and inhibit their activity. One 
example is the growth hormone-binding protein (GHBP), which derives from 
proteolytic shedding of the GH receptor (GHR) extracellular domain and is 
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complexed to a substantial fraction of circulating GH (Wang et al., 2002). 
Proteolytic shedding of receptors may not just release ligands or ligand binding 
proteins but can also be a means to regulate receptor function. For instance, one 
of the mechanisms that has evolved to modulate TNF function is the proteolytic 
cleavage of its cell surface receptors (Xanthoulea et al., 2004). The biological 
relevance is highlighted by identifications of mutations affecting shedding of the 
p55TNF receptor that have been linked with the development of the TNFR-
associated periodic syndromes (McDermott, 2001). Our studies support a model 
by which the full length, membrane-bound form of Tmem27 is responsible for 
stimulating cell replication: i. Over-expression of full-length Tmem27 in β cell 
lines and non-β cells that do not cleave Tmem27 leads to increased cell 
replication, ii. Over-expression of a truncated form in β cells and non-β cells has 
no effect on cell replication, and iii. Conditioned media or co-culture experiments 
failed to provide evidence that the soluble form of Tmem27 stimulates cell 
replication. These studies indicate that identification of the cleavage enzyme that 
processes Tmem27 could be therapeutically used to develop drugs that inhibit 
the activity of this protease. Such an inhibitor may therefore reduce cleavage of 
Tmem27 and lead to constitutive receptor activation, thereby increasing β cell 
mass. The role of the extracellular, soluble form of Tmem27 is currently 
unknown and future studies need to establish if it serves as a ligand, a ligand-
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binding protein or a receptor. However, its unique properties, including 
pancreatic β cell-specific and constitutive release, make it tempting to 
hypothesize that it may be exploited in the future as a biomarker for islet mass if 
sensitive RIAs or ELISAs can be developed to detect this protein in serum 
samples.  
3.4 Tmem27 influences insulin secretion  
 In MIN6 cells overexpression of Tmem27 leads to a decrease in insulin 
secretion while electroporation of cells with si-Tmem27 increases insulin 
secretion.  These data contradict recent findings by Fukui et al. that show 
Tmem27 augments insulin secretion in INS1 cells through its interaction with the 
SNARE complex.  I failed to detect this interaction through immunoprecipitation 
of Tmem27 from MIN6 cells.  I further show immunofluorescence data that 
refute  interaction of Tmem27 with VAMP-2 and syntaxin-1, components of the 
SNARE complex.  Additional experiments are necessary to illuminate the cause 
for the differences in both sets of data, however, one explanation may be the 
different expression levels of Tmem27.  When I electroporate MIN6 cells with 
either pTmem27 or si-Tmem27, western blots show marked increase or decrease 
in protein levels.  Representative immunoblots in the Fukui et al. show less 
robust regulation of Tmem27 in INS1 cells.  Thus levels of protein expression 
may specify thresholds for Tmem27 function.  This hypothesis may also explain 
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the lack of islet hypertrophy in RIP-Tmem27 transgenic mice generated by Fukui 
et al.  The Tmem27 protein levels display slight increase in islets of transgenic 
animals compared to wild-type controls.  Another major difference between the 
two studies is the β cell lines that are used to measure insulin secretion.  All my 
experiments were done in MIN6 cells that were transiently transfected whereas 
Fukui et al. used INS1 cells that stably overexpress Tmem27.  It is possible to 
postulate that long-term overexpression of Tmem27 may affect cell lines 
differently.  Moreover, I show that endogenous Tmem27 does not co-localize 
with SNARE complex proteins with immunofluorescence on primary islets, 
which is a more physiologically relevant approach than INS1 cells that are 
clonally selected.    
3.5 Tmem27 stimulates β cell growth in vivo 
 In this study I have also established that Tmem27 controls islet growth in 
vivo. The expression of Tmem27 is reduced in Tcf-1–/– mice and increased in three 
animal models of islet hypertrophy: ob/ob, db/db and aP2-Srebp-1c transgenic mice.  
I also show that expression of Tmem27 is correlated with islet mass in the BKS-
Lepr/J mice.  It is interesting that expression of Tmem27 is also increased in the 
hypertrophic kidneys after renal ablation, indicating that it may play a role in 
compensatory growth responses to organ injury (Zhang et al., 2001). 
Significantly, two independent lines of transgenic mice with increased expression 
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of Tmem27 in pancreatic β cells exhibited a ≈2-fold increase in pancreatic islet 
mass and insulin content. Over-expression of Tmem27 in β cells had no effect on 
non-β cell mass, further supporting the notion that the full-length, membrane 
bound form is responsible for stimulating cell growth. Although under normal a 
chow fed diet I did not observe alterations of glucose homeostasis, increased β 
cell mass together with unaltered glucose sensing would likely be beneficial in 
insulin resistance states. Thus I challenged the transgenic animals and their 
littermates with a high fat diet.  The high fat diet did not lead to any differences 
in weight gain or fasting glucose levels between the two sets of mice.  However, 
intraperitoneal glucose tolerance tests show that transgenic animals are more 
glucose responsive than their littermates.  Future studies with loss-of-function 
and gain-of-function mutations will further elucidate the role of Tmem27 in the 
maintenance of islet mass and insulin secretion.   
Adult pancreatic β cells retain a significant proliferative capacity as islet 
mass is adaptable to metabolic demand in the body.  Β cell proliferation is 
controlled by the cell cycle molecular machinery.  The earliest account of β cell 
mass regulation by cell cycle alterations came from studies in transgenic mice 
overexpressing SV40 large T-antigen in the β cell.  These mice displayed 
increased β cell replication, islet hyperplasia, and consequently insulinomas 
(Hanahan, 1985).  SV40 large T-antigen promotes proliferation by inactivating 
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p53 as well as the retinoblastoma tumor suppressor protein (pRb), both 
important in the G1 checkpoint of the cell cycle (Sherr, 2000; Levine, 1997).  
Supporting data for the importance of G1 checkpoint in β cell proliferation was 
obtained from cdk-4 deficient mice that display β cell hypoplasia causing 
neonatal diabetes (Rane et al., 1999).  Moreover, a knocked-in constitutively 
active cdk-4 allele results in beta cell hyperplasia.  D-cyclins are also key 
regulators of G1 phase. Two members of this family, cyclin D1 and cyclin D2, 
have been shown to be important in β cell replication and growth (Zhang et al., 
2005; Georgia and Bhushan, 2004).  I investigated whether increase in cell 
replication caused by Tmem27 expression was mediated by cdk-4 or cyclin D1.  I 
checked the levels of each protein in western blots 48 hours after MIN6 cells were 
transfected with an expression vector of Tmem27.  I could not detect a difference 
in the expression levels of either protein (data not shown).  
A number of growth factors have been identified as capable of increasing 
β cell replication including lactogens, insulin, insulin-like growth factors (IGFs), 
hepatocyte growth factor (HGF), and glucagon-like peptide-1 (GLP-1).   
Lactogens include placental lactogen (PL), prolactin (PRL), and growth 
hormone (GH).  Role of lactogens in regulation of β cell mass and function has 
been studied extensively during pregnancy.  PL and PRL signal through a 
common PRL receptor (PRLR).  Both PRLR and GH receptor (GHR) belong to the 
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cytokine family of receptors that interact with members of the Janus Kinase 
(JAK) family of tyrosine kinases (Bole-Feysot et al., 1998).  JAKs, upon 
phosphorylation, bind to members of the Signal Transduction and Activators of 
Trancription (STAT) family of transcription factors, which then translocate to the 
nucleus and activate expression of genes.  Recent studies indicate that β cell 
replication induced through the PRLR is dependent on the activation of 
JAK2/STAT5 signalling pathway that results in the modulation of cyclin D2 
expression (Friedrichsen et al., 2001 and 2003).    
Insulin, IGF-I and IGF-II all have been shown to be important for growth 
and cell proliferation during embryogenesis and adult life.  Insulin and IGF-I 
bind to tyrosine kinase receptors called insulin receptor (IR) and IGF-I receptor 
(IGF-IR), respectively.  IGF-II can bind to both receptors.  In vitro data obtained 
from β cell lines as well as isolated islets demonstrated that IGF-I and IGF-II 
increased β cell replication.  IGF-I most likely leads to the activation of Erk1/2, 
phosphoinositide 3 (PI3)-kinase and subsequently mTOR/p70(S6K) signaling 
pathways through the insulin receptor substrate (IRS)-2 (Lingohr et al., 2002). 
In vitro studies and transgenic mice overexpressing HGF in β cells suggest 
that HGF might be important for β cell proliferative response during insulin 
resistance, obesity, and partial pancreotectomy. HGF binds with high affinity 
and activates the transmembrane receptor encoded by the c-met protooncogene 
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(Furge et al., 2000).  In the β cell line INS-1, HGF-induced cell replication 
involves signaling through PI3 kinase and atypical PKCs (Gahr et al., 2002).  
However, conditional knockout mice with disrupted HGF/c-met signaling in β 
cells display normal β cell mass and proliferation suggesting that HGF is not 
essential for normal β cell growth and proliferation (Roccisana et al., 2005).  
In addition to the lactogens produced during pregnancy, the only well 
characterized stimulant for beta cell growth in a physiological situation is the 
gastrointestinal incretin hormone GLP-1.  GLP-1 binds to the seven-
transmembrane-spanning G protein-coupled receptor GLP-1R and has been 
shown to control blood glucose levels by stimulating insulin secretion, insulin 
biosynthesis, β cell proliferation and by inhibition of gastric emptying and 
glucagon release (Drucker, 2006).  GLP-1 stimulated β cell proliferation in studies 
using isolated islets and β cell lines appears to involve activation of genes such as 
c-jun, junD, nur77 and c-fos (Buteau et al., 2001; Susini et al., 1998).  These studies 
and others also implicate the involvement of signaling molecules such as PI3 
kinase, Akt/PKB and PKCζ (Buteau et al., 1999; Wang et al., 2004; Buteau et al., 
2001). 
 Recent evidence emphasizes the importance of PI3 kinase and Akt 
signaling in regulation of β cell mass as various growth factors has been shown 
to activate these molecules.  In β cells, the molecules and mechanisms that 
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mediate Akt signaling is not well defined.  However, in vivo and in vitro 
experiments suggest that Akt could mediate proliferative signals induced by 
activation of Irs-2 (White, 2002).  One of the mechanisms used for cell cycle 
regulation by Akt is inhibition of glycogen synthase kinase 3β (GSK3β) by 
phosphorylation.  This inhibition leads to cyclin D1 and c-Myc accumulation in 
the nucleus and reduced levels of the cell cycle inhibitor p21CIP (Chang et al., 
2003).  Akt has also been shown to regulate cell cycle by inactivation of the Foxo 
family of transcription factors (Martinez-Gac et al., 2004).  Overexpression of 
Foxo transcription factors causes inhibition of cell proliferation (Chang et al., 
2003).  Moreover, decreased levels of Foxo1 restore Pdx1 expression and β cell 
proliferation in mice deficient in Irs-2, suggesting that Akt induced proliferative 
signals can be mediated by Foxo1 and Pdx1 (Kitamura et al., 2002).         
It will be important to elucidate the exact molecular mechanisms Tmem27 
utilizes in order to regulate cell replication.  Tmem27 might exert its effects 
through one of the pathways described above and further experiments are 
necessary in order to determine specific signaling events.  Activation of 
previously described signaling molecules for growth such as JAK/STAT, Erk1/2, 
PI3 kinase,  and Akt should be checked following Tmem27 expression.  I did not 
find an increase in the expression levels of cell cycle modulators such as cdk-4 
and cyclin D1 upon Tmem27 expression, however, control of cell cycle is very 
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complicated and requires a precise balance of many different proteins.  Further 
experiments should be performed in order to distinguish which molecules 
mediate the growth effect of Tmem27. 
3.6 Conclusion 
 In this thesis I have identified and characterized a novel growth factor in 
pancreatic β cells.  I show that Tmem27 expression is directly regulated by Tcf1 
elucidating a link between the mutated transcription factor and its consequent 
islet mass phenotype.  I demonstrate that Tmem27 undergoes ectodomain 
shedding, however, the function of this process needs to be elucidated.  The data 
collectively suggest that full-length Tmem27 is responsible for the proliferation 
response.  Thus we speculate that release of the extracellular domain may be a 
signal used to regulate replication of β cells of the islet (Figure 59).  Identification 
of the protease in control of Tmem27 shedding and the functional relevance of 
this cleavage is crucial.  Such studies will validate Tmem27 or its inactivating 
protease as a novel pharmacological target for the treatment of diabetes. 
 
 










                       
 









All animal models were housed in Laboratory of Animal Research Center 
(LARC), a pathogen-free animal facility at the Rockefeller University. The 
animals were maintained on a 12 hours light/dark cycle and fed a standard 
rodent chow.  Genotyping of transgenic mice was performed on DNA isolated 
from 3 weeks old mice by PCR (Lee et al., 1998).  
 
Vectors 
The reporter plasmid pT27luc-wt was generated by cloning an 815-bp fragment 
of the mouse Tmem27 promoter into pGL2-luciferase. The reporter plasmids 
pT27luc-m1 and -m2 are identical to pT27luc-wt except for mutated TCF1 
binding sites at positions -56 to –59 and –116 to –119. Vector pTmem27.V5 is 
generated by cloning a PCR fragment of 696 bp that encompasses 30 bp of 5’UTR 
of Tmem27 cDNA and the rest of the open reading frame except for the stop 
codon into pcDNA3.1/V5-His-TOPO vector from Invitrogen. Vector pTmem27-
V5.del. was generated by deleting amino acid residues 17-129 of pTmem27.V5 





Two peptides (anti-Tmem27N: VQSAIRKNRNRINSAFFLD and anti-Tmem27C: 
GIPCDPLDMKGGHINDGFLT) were synthesized and processed to >90% purity, 
conjugated to KLH and used for immunization of rabbits (Bethyl Laboratories, 
Texas). Antisera were affinity purified and tested by western blotting and 
immunohistochemistry. Affinity purified antisera were used for all studies. 
Other antibodies used for immunoblotting and immunohistochemistry were 
obtained from the following sources: anti-insulin (Linco), anti-glucagon (Linco), 
anti-V5 (Invitrogen), anti-Tcf1 (Active Motif), anti-HA (Covance), anti-Glut2 
(R&D Systems), anti-synaptophysin (Chemicon), anti-somatostatin (Cell 
Marque), anti-PP (Linco), and anti-Pdx1 (gift from Chris Wright). Rhodamine red 




MIN6 cells were cultured with DMEM medium containing 25 mM glucose, 15% 
fetal bovine serum, and 5.5 µM 2-mercaptoethanol. INS-1 cells were cultured 
with RPMI 1640 medium containing 11.1 mM glucose and 5% fetal bovine serum 
and 10 mM Hepes, pH7.4.  HepG2 cells were cultured with DMEM medium 
containing 25 mM glucose and 10% fetal bovine serum. Pancreatic islets were 
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cultured in RPMI-1640 medium.  S2 cells were cultured in Schneider’s Medium 
with 10% FBS. 
 
Transient transfections and luciferase assay 
Fugene reagent (Roche) for HepG2 cells and Lipofectamine 2000 (Invitrogen) for 
MIN6 cells were used according to the manufacturer’s directions in transient 
transfections.  0.5 µg of luciferase reporter construct, expression vector and 
CMV-LacZ were added per 35 mm dish.  Luciferase was normalized for 
transfection efficiency by the corresponding β-galactosidase activity (Shih et al., 
2001). 
 
Crosslinking of proteins in cell lysates 
MIN6 cells, grown to 90% confluency in 6 well plates, were harvested and 
resuspended in reaction buffer and reagent in 50 µl volume and incubated for 2 
hrs at 4˚C.  Reactions were stopped by adding 50 mM Tris-Hcl, pH 7.4 for 10 min 
on ice. Cells were then washed with PBS and lysed in RIPA buffer in the 
presence of protease inhibitors for 15 min at 4˚C.  Cell lysates were centrifuged 
for 5 min at 10,000 x g and the supernatants were subjected to reducing and non-
reducing SDS-PAGE followed by immunoblotting. Crosslinking reagents and 
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buffers:  BMH (Pierce) was dissolved in DMSO and incubated in PBS, and DTBP 
(Pierce) was dissolved in water and incubated in 0.2 M triethanolamine pH 8.0. 
 
Inhibition and enzymatic cleavage of N-glycosylation 
MIN6 cells that express pV5-TMEM27 were incubated with indicated 
concentrations of tunicamycin (Sigma) dissolved in DMSO and with DMSO 
alone for 12 h at 37˚C. Cell lysates were then subjected to SDS-PAGE and 
immunoblotting with anti-V5 antibody.   
Intact N-linked glycans were removed from secreted portion of TMEM27 with 
the recombinant enzyme N-glycanase (Prozyme, San Leandro, CA).  
Supernatants from MIN6 cells and pancreatic islets were denatured in 20 mM 
sodium phosphate pH 7.5, 0.1% SDS and 50 mM β-mercaptoethanol by heating at 
100˚C for 5 min.  NP-40 was added to a final concentration of 0.75 % and reaction 
was incubated with N-glycanase for 3 h at 37˚C.  
 
Electrophoretic mobility shift assays (EMSA) 
EMSA analysis was performed as described previously (Shih et al., 2001) with 
minor modifications. Assay was performed with 10 µg of whole cell extracts in 
binding buffer (20 mM Hepes, pH 7.9, 10 % glycerol, 150 mM NaCl, 1 mM DTT).  
Whole cell extracts were incubated with 32P-labeled double stranded 
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oligonucleotide probes containing the wildtype or mutant Tcf1 binding sites in 
the TMEM27 promoter (sequences: 5’-GGAGATTTTCGTAAATAACTGACA -3’, 
5’-GGGCGTTAATTATTAAACCTTTTA-3’ and 5’-GGGCAGAGATTATTAAA 
CCTTTTA-3’, respectively). Cold competitor was an unlabeled double-stranded 
oligonucleotide containing the Tcf1 binding site in the Fxr-1 promoter (sequence: 
5'−GATGGGGGTTAATCAAGTAAACCACAC−3'). Supershifts were carried out with an 
anti-Tcf1 antibody (Geneka Biotechnology Inc., Montreal, Canada). ChIP analysis 
was carried out using isolated primary hepatocytes and isolated islets from 
C57/B6 mice or MIN6 cells, and the ChIP Assay kit (Upstate Cell Signaling 
Solutions, Lake Placid, NY) according to the manufacturers protocol. Tcf1 was 
precipitated with anti-HNF-1 antibody and DNA was amplified using primers  
sequences: 5’-ACAGGAGGCAGGTGGGAGGCTTCT -3’ and 5’-CCCGGA 
TTAGGGTATCGGAGAA -3’).  Primers for apoM were 5’-GGGCTCAG 
CTTTCCTCCTA-3’ and 5’-CTCCGCCTTAACTGTTCTCTGATG -3’). 
 
Whole Cell extract preparation 
MIN6 cells were grown to 90% confluency in 150 mm tissue culture dishes. Cells 
were washed once in ice-cold PBS and scraped into 3 ml PBS.  Cells were 
centrifuged at 4,000 x g for 4 min and resuspended in 2 volumes of high-salt 
extraction buffer (400 mM KCl, 20 mM Tris, pH 7.5, 20 % glycerol, 2 mM DTT, 1x 
 83
complete TM protease inhibitors (Boehringer Mannheim), and 20 µg/mL 
Aprotinin).  Cell-lysis was performed by freezing and thawing, and the cellular 
debris was removed by centrifugation at 16,000 x g for 10 min at 4˚C.   
 
Pulse-Chase experiment with 35S-labeled Tmem27 
2 x 105 MIN6 cells were plated in 35 mm dishes and incubated in methionine-free 
DMEM (DMEM-Met) for 70 min at 37oC.  200 µCi/mL of [35S]methionine was 
added to DMEM-Met and cells were labeled in this media for 2 hours at 37oC.  At 
the end of the pulse period, MIN6 cells were chased with complete growth 
medium for different periods.  At the indicated time points, supernatants were 
collected and cells were lysed for immunoprecipitation.  Cells were washed in ice 
cold PBS five times and scraped into PBS and centrifuged for 5 min at 2000 rpm.  
Cells were suspended in lysis buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% 
NP40, 1mM EDTA and protease inhibitors) and sonicated 5 sec for 4 times.  
0.25% sodium deoxycholate was added to the samples, which were then mixed 
and incubated on ice for 15 min.  Samples were centrifuged for 15 min at max 
speed at 4oC and the supernatant from the lysates were immuno-precipitated 
with α-Tmem27C for 16 hours at 4oC followed by incubation with Protein G-
Sepharose for 1 hour.  Collected MIN6 supernatants were adjusted to 20 mM 
Tris-HCl pH 7.4 and 1% NP40 along with protease inhibitors.  α-Tmem27N 
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antibodies were used to immunoprecipitate cleaved protein for 16 hrs at 4oC 
followed by incubation with Protein G-Sepharose for 1 h.  The sepharose beads 
were washed in ice-cold PBS 5-times for 5 min each and resuspended in SDS 
sample buffer (2% SDS, 62.5 mM Tris, pH 6.8).  Samples were boiled for 5 min 
and supernatants were run on 4-15% gradient SDS gels.  Gels were processed for 
autoradiography and exposed on film.   
 
In vitro insulin secretion and hormone measurements  
Mouse islets were isolated and incubated in different glucose concentrations 
after an overnight culture.  Insulin and glucagon were extracted from pancreata 
with acid ethanol (10% glacial acetic acid in absolute ethanol), sonicated for 10 
min, and centrifuged 2 times at 4°C at 12,000xg for 10 min. Supernatants were 
collected and stored at -20°C for insulin and glucagon determinations by using 
sensitive  RIA kits (Linco Research). 
 
Pancreatic islet and RNA isolation 
Pancreatic islets were isolated from 6 to 8 week-old mice. We used collagenase 
digestion and differential centrifugation through Ficoll gradients, with a 
modification of procedures previously described (Shih et al., 2002). Total RNA 
was then extracted using TRIzol reagent (Gibco-BRL) and following the 
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manufacturer’s instructions. Contaminating genomic DNA was removed using 
1µl of RNase free DNase-I (Boehringer) per 5µg of RNA.  
 
Islet morphometry 
The pancreata were fixed in paraformaldehyde and stained for insulin and pool 
of glucagon, pancreatic polypeptide and somatostatin as described above. 
Sections (7m) through the entire pancreas were taken, and every sixth section 
was used for morphometric analysis. At least 288 non-overlapping images (pixel 
size 0.88m) were scanned using a confocal laser-scanning microscope (Zeiss 
LSM 510, Germany). The parameters measured in this study were analyzed 
using integrated morphometry analysis tool in the Metamorph Software Package 
(Universal Imaging Corporation, PA). The area covered by cells stained by 
insulin or non-β cell pool was integrated using stained objects that are greater 
than 10 pixel in size. 
 
RT-PCR 
Total RNA was extracted using TRIZOL reagent (Invitrogen) and 10 g of RNA 
was treated with 5U of RNase-free DNase-I (Ambion). cDNA was synthesized 
using Moloney leukemia virus reverse transcriptase with dNTPs and random 
hexamer primers (Invitrogen). The cDNAs provided templates for PCRs using 
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specific primers in the presence of [-32P]dCTP and Taq polymerase as previously 
described (Shih et al., 2001).  Quantitative PCR was performed using the 
Sequence Detection System 7700 (Applied Biosystems) for amplification and 
specific sequence detection. Forward and reverse PCR primers were used at a 
final concentration of 300 nM, and probes, containing a 5' fluorophor (6-FAM) 
and a 3' quencher (TAMRA), were used at a final concentration of 100 nM. 
Expression of Tmem27 was evaluated relative to the mRNA expression of the 
housekeeping gene -actin in the same sample. Cycling parameters were: 2 min, 
50°C; 10 min, 95°C; and 40 times: 30 s, 95°C; 1 min, 60°C. Primers and probes 
were purchased from Applied Biosystems. 
 
Immunoblotting and Immunohistochemistry 
Cytosolic protein extracts were separated by SDS-PAGE (4-15%) and transferred 
onto a nitrocellulose membrane (Schleicher & Schuell) by electroblotting. 
TMEM27 was detected with anti-Tmem27N and anti-Tmem27C antisera (1:500). 
Membranes were incubated with primary antibodies overnight at 4°C. 
Incubations containing the secondary antibody were performed at RT for 1 hr. 
SDS-PAGE under non-reducing conditions was performed under conditions 
omitting DTT from the sample buffer. 
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MIN6 cells were plated on coated slides (Nalge Nunc Int.) and fixed with 4% 
paraformaldehyde at 4˚C for 20 min.  Mouse islets were dissociated for 5 min at 
37oC in the presence of 0.01% Trypsin-EDTA and were plated in collagen coated 
slides and fixed the same way. Slides were incubated in 0.01% saponin with 3% 
normal donkey serum in PBS for 30 min at room temperature and anti-
Tmem27N and anti-Tmem27C (1:20) were added overnight at 4˚C along with 
anti-insulin (1:600), anti-Glut2 (1:50), and anti-synaptophysin (1:500).  Secondary 
antibodies were added for 30 min at RT.    
Pancreata were fixed in 4% paraformaldehyde at 4˚C for 4 h and embedded in 
paraffin.  7 µm sections were cut and after deparaffinization, antigen-unmasking 
was performed by microwaving slides in 0.01 M sodium citrate pH 6.0.  Sections 
were permeabilized in 0.1 % Triton-X-100 and incubated in 3 % normal donkey 
serum in PBS for 30 min. Staining was completed as above. 
 
Electron microscopy studies 
MIN6 cells were fixed in 4% paraformaldehyde and 0.02% glutaraldehyde in 0.1 
M cacodylate buffer, pH 7.4 for 2 hours. The cells were washed with PBS and 
embedded in 10% gelatin and refixed as above. Cell pellets were cryo-protected 
using a 2.3M sucrose solution in PBS, and samples were stored in liquid nitrogen 
until use (Griffith et al., 1983). Cryo, ultrathin sections were cut using glass 
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knives in a Reichert-Jung FC-4E cryo-ultramicrotome. The sections were 
collected on Formvar-carbon coated nickel grids, blocked with 1% BSA-PBS and 
incubated with anti-Tmem27C at a 1:10 dilution. Incubation was stopped by 
washing 2 times with PBS, 15 min each. The sections were then incubated with 
goat anti-rabbit IgG conjugated to 10 nm gold particles (Amersham Life Science, 
Arlington Heights, IL). The grids were processed and stained as desribed 
previously (Tokuyasu et al., 1973). 
 
Thymidine incorporation studies 
[3H]Thymidine incorporation in 5 x 104 cells/well in 24-well culture plates was 
assayed as follows.  48 hrs after electroporation, cells were incubated in growth 
arrest medium (0.5% FCS) for the next 24 hours and then incubated for an 
additional 24 hours in normal growth medium.  For the last 4 h of the incubation, 
0.25 µCi/well [3H]methylthymidine (Perkin Elmer) was added.  After completion, 
cells were rinsed twice in ice-cold PBS, and incubated with 10% trichloroacetic 
acid (TCA) on ice for 20 min.  After washing with 10% TCA, cells were 
solubilized in 0.2M NaOH/1% SDS for 10 min at room temperature.  TCA-
insoluble materials were neutralized with 0.2M HCl, and radioactivity was 




Synthetic siRNAs were synthesized by Dharmacon Research (Lafayette, CO).  
siRNAs were designed for mouse TMEM27 (NM_020626) and Luciferase. The 
target sequences of siRNAs are: siTMEM27#1:  gaagtacagtcggccataa, 
siTMEM27#2:  ctacctatgctgatttaat. 3µg of each siRNA per 1 x 106 cells were 
electroporated into MIN6 cells.  
 
Generation of adenovirus 
Adenovirus construct was generated by building a minigene with the addition of 
the intron between exon 1 and exon 2 to human Tmem27 cDNA.  Sequence for 5’ 
UTR, exon 1, intron 1, exon 2, and first 60 nucleotides of exon 3 were cloned into 
pcRII-TOPO (Invitrogen).  This construct was digested with EarI and BstXI to 
obtain a 756 bp fragment and inserted into pcDNA3.V5 (BstXI and NotI) along 
with the 549 bp fragment taken out of Tmem27-pcDNA3.V5 with EarI and NotI.  
The minigene construct in pcDNA3.V5 was digested with HindIII and AvrII.  
The fragment was inserted into pCMV-Adenovirus vector digested with HindIII 





Generation of transgenic lines  
Human Tmem27 cDNA was cloned next to 949 bp of the rat insulin promoter 
(RIP) in pcRII-TOPO vector (Invitrogen).  Both transgenic lines were generated 
by pronuclear injection of the promoter and cDNA sequence that was extracted 
from the vector construct with NsiI.  Transgenic lines are genotyped by southern 
blotting using AflII and NcoI that yields different patterns for both lines.    
 
Bacterial protein production for monoclonal and polyclonal antibodies 
Human Tmem27 sequence for amino acids 15-121 was subcloned into pGEX-4T-1 
(Amersham) in frame with glutathione s-transferase (GST) includng a cleavage 
site for thrombin.  BL21 cells were transformed with construct and soluble 
protein was produced by inducing with 0.25 mM IPTG.  Briefly, cultures were 
induced with IPTG when reached OD reading of 0.6 at A600.  Cultures were 
further incubated at 37 oC shaking for 5 hours.  Bacteria was centrifuged at 6000 
rpm for 10 min and dissolved in ice cold PBS that contains protease inhibitors (50 
µl PBS per 1 ml of culture).  Solutions were sonicated at power 3 for 3 times 15 
seconds each with a 1 minute cooling period between each pulse.  Triton-X-100 
was added to solutions to a concentration of 1% and tubes were rotated at 4oC for 
30 minutes.  Bacterial lysates are centrifuged at 25000 rpm for 25 min at 4oC and 
the supernatant is filtered with 45 µm syringe filters.  Supernatants were 
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incubated overnight at 4oC with GST-coupled beads and the next day beads were 
washed three times in ice cold PBS.  The protein was eluted for ½ hr in 50 mM 
Tris pH 8.0, 10 mM reduced glutathione, and 5 mM β-octylglucoside.  Eluted 
protein was dialyzed 16-24 hrs in 50 mM Tris pH 8.0 and concentrated in 
Microcon YM-3 centrifugal units. 
 
S2 cell protein production for a polyclonal antibody 
Sequence spanning amino acids 15 to 121 of human Tmem27 was cloned in 
frame to vector pMT/BiP/V5-His (Invitrogen) to create hTmem27-pMT/BiP/V5. 
S2 cells were transfected using CaPO4 with hTmem27-pMT/BiP/V5 or GFP-
pMT/BiP/V5. Briefly, S2 cells were seeded in 6 well plates (1.5 x 106 cells in 3 ml) 
and transfected 24 hours later.  Solution A was prepared by adding 36 µl of 2M 
CaCl2 and 19 µg DNA to a total volume of 300 µl with sterile water.  Solution B 
was 300 µl of 2x Hepes buffered saline (HBS).  Solution A was added to solution 
B in a dropwise fashion while bubbling through with a pipette over 2 minutes.  
The mixed solution is incubated at room temperature for 45 minutes and added 
in drops while swirling the cells.  In 24 hours, cells are centrifuged at 800 rpm for 
10 minutes and washed twice with fresh medium.  BiP is a secretion signal and 
hTmem27-V5 is secreted into the supernatant when S2 cells expressing 




Two complementary oligonucleotides approximately 30 bps long were generated 
with the desired mutation in the middle of the sequence.  PCR reaction was 
prepared with 125 ng of each primer and 50 ng DNA template.  PCR conditions 
were as the following: 
Segment Cycles  Temperature  Time 
1  1  95oC   30 sec                                      
2  12  95oC                        30 sec       
    55oC   1 min 
    68oC   6 min                             
Following cycling reaction was cooled to 37oC and digested with DpnI (20u) for 1 
hour.  50 µl DH5α bacteria was transformed with 5 µl of digested PCR reaction 
and plated overnight for colony growth.                                   
Protease Inhibitors 
Inhibitor Chemical Name 
Pefabloc [4-(2-Aminoethyl)benzenesulfonylfluoride.HCl] 
Aprotinin  
Leupeptin Acetyl-Leu-Leu-Arg-al hydrochloride 
PMSF Phenylmethanesulfonyl fluoride  
E64d (2S,3S)-trans-Epoxysuccinyl-L-leucylamido-3-
methylbutane ethyl ester 
Phosphoramidon -( -Rhamnopyranosyloxyhydroxyphosphinyl)-Leu-Trp 
disodium salt 




Results are given as mean ± SD. Statistical analyses were performed by using a 
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